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Abstract
While human astroviruses (HAstV) were discovered nearly 45 years ago, these small positive-sense RNA
viruses remain critically understudied. These studies provide fundamental new research on astrovirus
pathogenesis and disruption of the gut epithelium by induction of epithelial-mesenchymal transition
(EMT) following astrovirus infection. Here we characterize HAstV-induced EMT as an upregulation of
SNAI1 and VIM with a down regulation of CDH1 and OCLN, loss of cell-cell junctions most notably at 18
hours post-infection (hpi), and loss of cellular polarity by 24 hpi. While active transforming growth factor-
(TGF-) increases during HAstV infection, inhibition of TGF- signaling does not hinder EMT induction.
However, HAstV-induced EMT does require active viral replication. These are among the first studies
describing the induction of EMT by a non-oncogenic virus and provides an exciting opportunity to
understand EMT induction independent of cancer. Our findings likely extend beyond astrovirus to other
viruses and may shed light on novel ways pathogens can circumvent the barriers meant to protect against
them. Crossing these barriers can lead to systemic and even fatal infections. Astroviruses can be
especially problematic in immunocompromised individuals and infants where the virus has been
associated with necrotizing enterocolitis, severe and persistent diarrhea, and even encephalitis and
meningitis. Using our novel tools and models, we demonstrate that the FDA-approved broad-spectrum
anti-infective drug nitazoxanide (NTZ) blocks astrovirus replication in vitro with a 50% effective
concentration (EC50) of approximately 1.47μM. It can be administered up to 8 hours post-infection and is
effective against multiple human astrovirus serotypes including clinical isolates. Most importantly, NTZ
reduces viral shed in vivo, exhibiting its potential as a future clinical therapeutic. Overall, these studies will
further our understanding of astrovirus pathogenesis leading to the development of therapeutic options
for vulnerable populations.
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ABSTRACT
While human astroviruses (HAstV) were discovered nearly 45 years ago, these
small positive-sense RNA viruses remain critically understudied. These studies provide
fundamental new research on astrovirus pathogenesis and disruption of the gut epithelium
by induction of epithelial-mesenchymal transition (EMT) following astrovirus infection.
Here we characterize HAstV-induced EMT as an upregulation of SNAI1 and VIM with a
down regulation of CDH1 and OCLN, loss of cell-cell junctions most notably at 18 hours
post-infection (hpi), and loss of cellular polarity by 24 hpi. While active transforming
growth factor- (TGF-) increases during HAstV infection, inhibition of TGF-
signaling does not hinder EMT induction. However, HAstV-induced EMT does require
active viral replication. These are among the first studies describing the induction of
EMT by a non-oncogenic virus and provides an exciting opportunity to understand EMT
induction independent of cancer. Our findings likely extend beyond astrovirus to other
viruses and may shed light on novel ways pathogens can circumvent the barriers meant to
protect against them. Crossing these barriers can lead to systemic and even fatal
infections. Astroviruses can be especially problematic in immunocompromised
individuals and infants where the virus has been associated with necrotizing enterocolitis,
severe and persistent diarrhea, and even encephalitis and meningitis. Using our novel
tools and models, we demonstrate that the FDA-approved broad-spectrum anti-infective
drug nitazoxanide (NTZ) blocks astrovirus replication in vitro with a 50% effective
concentration (EC50) of approximately 1.47μM. It can be administered up to 8 hours postinfection and is effective against multiple human astrovirus serotypes including clinical
isolates. Most importantly, NTZ reduces viral shed in vivo, exhibiting its potential as a
future clinical therapeutic. Overall, these studies will further our understanding of
astrovirus pathogenesis leading to the development of therapeutic options for vulnerable
populations.
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CHAPTER 1.

ASTROVIRUS VIROLOGY, PATHOGENESIS, AND DISEASE
Virology

Astroviruses are small, non-enveloped, single stranded, positive sense RNA
viruses that infect a wide variety of host species. Human astroviruses (HAstV)
consistently rank among the leading causes of diarrhea especially in the young, elderly
and the immunocompromised. Yet disease can range from asymptomatic to severe central
nervous system (CNS) symptoms including encephalitis and meningitis. Despite the dire
need for further research, much astrovirus virology and pathogenesis remains
understudied. This chapter summarizes the body of literature published on astrovirus
while highlighting the areas where further research is needed to better understand this
interesting virus.
Classification
In 1975, astrovirus was first discovered in the stool of infants with
gastroenteritis.1 It was named for the star-like morphology of the virions’ capsid under
electron microscopy noted by Madeley and Cosgrove.2,3 With the availability of the
complete viral genome sequence in 1993, astrovirus was classified into a new family,
Astroviridae.4 Now, Astroviridae is divided into two genera: Avastrovirus, viruses
infecting avian species, and Mamastrovirus, viruses infecting mammalian species5
(Figure 1-1). Avastrovirus and Mamastrovirus are further split into two genogroups
based on the genetic relatedness within the hypervariable capsid protein.
Following the discovery of HAstV, eight closely related but genetically distinct
serotypes were identified. These eight serotypes are known as human astrovirus type 1
through 8 (HAstV-1–8) and are commonly referred to in the field as the classical HAstV.
In 2008, using new unbiased full-genome sequencing and pathogen discovery techniques,
two additional HAstV clades were identified and named for the locations where they
were discovered: Melbourne (HAstV-MLB) and Virginia (HAstV-VA/HMO).6–10
HAstV-VA-like viruses were also discovered in Nigeria, Pakistan, and Nepal11 and
termed HMO because of their genetic similarity to human, mink and ovine astroviruses.
To date, the HAstV-MLB clade contains at least three strains, MLB1,8,9,12 MLB2,6,10 and
MLB3,6,10 and the HAstV-VA/HMO clade contains five strains, VA1,7,11 VA2,11 VA3,11
VA4,6 and VA5.13 The HAstV-MLB and HAstV-VA/HMO viruses have been designated
as non-canonical or novel human genotypes, due to their genetic relatedness to nonhuman, mammalian astroviruses rather than the classical.
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Figure 1-1. Phylogenetic Tree of Astroviruses.
General phylogeny tree of Astroviridae constructed using capsid protein amino acid
sequences. Astroviridae is divided into four genogroups based on whether the species a
strain infects is mammalian or avian and the genetic relatedness within the hypervariable
capsid protein.
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Genome
Astroviruses belong to group IV of the Baltimore classification of viruses as they
have positive sense, single stranded RNA genomes approximately 6.2 to 7.7 kb. The
genome has three open reading frames (ORFs) with a 5′ viral genome-linked protein
(VPg) and a 3′ poly(A) tail4,14,15 (Figure 1-2A). ORF1a and ORF1b encode the
nonstructural proteins. Astrovirus is believed to have as many as five nonstructural
proteins;16–22 however, only three, a serine protease, a viral genome linked protein (VPg),
and an RNA-dependent RNA polymerase (RdRp),22 have been fully described. There is a
ribosomal frameshift signal between ORF1a and ORF1b which allows for the translation
of the RdRp.14,23,24 ORF2 encodes the astrovirus capsid protein and is expressed in excess
via a highly conserved subgenomic RNA (sgRNA) promoter. This allows for astrovirus
capsid protein to be translated at a higher level for assembly of new virions during the
viral replication cycle.
Virus Structure
The star-like appearance of astrovirus noted on about 10 percent of virions by
Madeley and Cosgrove is due to spikes studded on the virion surface.3,25 The crystal
structures for the HAstV-8 spike,26 HAstV-1 full capsid,27,28 HAstV-2 spike,29 and turkey
astrovirus type 2 (TAstV-2) spike30 have been described using electron and cryo-electron
microscopy, X-ray crystallography, and density ultracentrifugation. Infectious astrovirus
particles are between 41 and 43 nm in diameter with T = 3 icosahedral symmetry
(Figure 1-2B) with significant similarities to the human hepatitis E virus capsid.28,31
The capsid protein is translated as an inactive 90 kDa precursor, known as VP90,
which is sequentially cleaved before it can be assembled into an infectious viral particle.
All capsid protein cleavage products are named according to their molecular weights.
Intracellular caspases are the first to cleave VP90, generating VP70.32,33 Multiple reports
have shown this caspase cleavage is essential for the release of newly formed virions.19,33
Once outside the cell, host proteases further cleave VP70 of the immature virions into
VP34, VP27, and VP25.22,34 VP34 makes up the continuous inner core, measuring about
35 nm in diameter, while VP27 and VP25 form the spike domains.35 While the immature
virion has about 90 spikes, the proteolytic cleavage process reduces that to just 30 spikes
on a mature, infectious particle.31 These spikes are thought to hold multiple putative
receptor-binding sites.29,34–36
The astrovirus capsid appears to also play a key role in the pathogenesis of the
virus. Studies have shown the capsid binds complement 1q37 and mannose-binding
lectin38 to inhibit both the classical and lectin pathways of complement. This may be why
there is not significant immune infiltration or histological changes during astrovirus
infection.39,40 In addition, the capsid has been shown to act as a novel enterotoxin in
vitro41 and in vivo,42 increasing barrier permeability independent of viral replication.
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Figure 1-2. Astrovirus Genome and Capsid Structure.
(A) The astrovirus genome is comprised of three open reading frames (ORF) as well as a
5’ viral genome linked protein (VPg) and a 3’ poly(A) tail. The known encoded proteins
are shown in the inset boxes. The lighter portions of ORF2 represent the hypervariable
regions. (B) Astrovirus virions have T=3 icosahedral symmetry. The capsid composed by
an inner core of VP34 and spike domains composed of VP25 and VP27.
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Replication Cycle
Many aspects of the astrovirus replication cycle remain undescribed. However,
with studies using a few of the classical HAstV genotypes, along with knowledge of
other closely related group IV viral families including Togaviridae and Caliciviridae, we
know the basic steps of the astrovirus replication cycle.
Entry
Despite dedicated research, the cellular receptor for astroviruses is still unknown.
Studies have shown different cell types do not share the same susceptibilities for HAstV
serotypes. For instance, human colorectal adenocarcinoma (Caco-2) cells are the gold
standard for HAstV infection and can support the replication of all classical HAstV
serotypes; however, baby hamster kidney (BHK-21) cells are only infected by HAstV-2,
and human colorectal carcinoma epithelial (HTC-15) cells are only infected by HAstV1.43 This supports the hypothesis that multiple receptors or binding factors may be needed
for cell entry. Crystallization of both the avian and human capsid and spike proteins
revealed conserved polysaccharide binding motifs30 and pretreatment of Caco-2 cells
with chondroitinase, but not heparinase, reduced infectivity.26,29 We also know astrovirus
disrupts cellular junction organization,41 which may further allow for a binding cascade
leading to a previously hidden cellular receptor. Nevertheless, additional research is
needed to describe the viral binding step.
Once the virus is bound to a host cell, studies using HEK293 and Caco-2 cells
have confirmed entry proceeds via clathrin-mediated endocytosis.44,45 Using electron
microscopy, astrovirus particles were detected in coated pits and vesicles.44 In addition,
inhibiting clathrin assembly with chlorpromazine and dansylcadaverine reduced HAstV-8
replication.45 After endocytosis, vesicles containing astrovirus particles are trafficked to
progressively more acidic endosomes and must reach late endosomes to uncoat the viral
genome. Studies blocking the acidification of endosomes with bafilomycin A1 and
silencing Rab7 significantly reduced HAstV-8 replication.45 Investigation of recombinant
viral-like particles (VLPs) identified divalent cations that stabilize the capsid structure.46
Therefore, an acidic environment and a low cation would both promote destabilization of
the capsid and uncoating of the genome.
Replication
HAstV genome replication occurs in intracellular membrane bound vesicles.47
Given that HAstV nonstructural polyprotein contains an endoplasmic reticulum (ER)
signal sequence and both the nonstructural proteins and genome colocalize with the ER,48
it is assumed these vesicles are derived from ER membrane. Since the viral genome is
positive-sense RNA, following release, it can be directly translated into protein. The first
proteins made after viral uncoating are the nonstructural proteins, nsp1a and nsp1ab,
encoded by ORF1a and ORF1b. The nsp1ab polyprotein is processed by the viral
protease, and possibly by yet unidentified host proteases, to form the nsp1b protein, the
viral RdRp.14 The nsp1a polyprotein is cleaved into several smaller proteins, some of
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whom have an undetermined function.16,18,20,22,49 One of the nsp1a proteins, nsp1a/4, a
putative VPg, has been shown to colocalize with viral genome and is thought to facilitate
viral replication.19,48,50 Although direct interaction between nsp1a/4 and the genome has
not been established, the production of infectious virus was significantly reduced when
the viral RNA was pretreated with proteinase K before transfection into permissive
cells,51 indicating some protein interaction is required for efficient replication. The
production of the capsid protein from ORF2 involves translation of both genomic and
sgRNA. Around 12 hours post-infection there is an excess of sgRNA produced, which
coincides with higher levels of capsid protein translation.52 This is characteristic utilized
by other positive-sense single-stranded RNA viruses meant to evade translational
repression by the host.53
We know multiple host proteins are necessary for astrovirus replication, however,
their exact role has yet to be fully elucidated. One study, using density gradient
centrifugation, free-flow zonal electrophoresis, and tandem mass spectrometry, identified
host proteins that associated with the same membrane fraction as viral proteins and
RNA.54 Silencing host proteins involved in fatty acid and cholesterol synthesis,
phosphatidylinositol and inositol metabolism, and RNA helicase activity, all decreased
the production of viral RNA, protein and infectious progeny of HAstV-8.54 Our lab has
demonstrated ERK1/2 is phosphorylated within 15 min of viral binding and this
phosphorylation event is required for efficient viral protein production and genome
replication.55 It has recently been determined the ubiquitin proteasome system is also
needed for replication of the viral genome and sgRNA.56
Assembly and Release
In the same membraned sites where replication takes place, viral capsids can selfassemble into full virions or virus like particles (VLP) without the presence of a viral
genome.46 Virions are processed and release occurs via an unknown, non-lytic
mechanism without causing significant cell death.33,57 Researchers have hypothesized that
astrovirus release may occur through a similar mechanism used by rotavirus or
poliovirus, or through a form of cell membrane destabilization.57
Pathogenesis
Molecular Mechanisms of Disease
Many astrovirus pathogenesis studies have been concentrated on elucidating the
mechanism by which the virus induces diarrhea. It is common for gastrointestinal
pathogens to breach the intestinal epithelium by inducing inflammation and cell damage
or death, and in doing so cause diarrhea. However, this is not the case with HAstV.
Astrovirus-induced diarrhea occurs without triggering cell death or inflammation,39,42
although one report demonstrated that HAstV-8 induced apoptosis in Caco-2 cells.33
Rather, HAstV is thought to cause diarrhea by increasing barrier permeability via the

6

disruption of intestinal cellular junctions.41,42,58,59 Cellular junctions are highly regulated,
multiprotein complexes that join neighboring cells, maintain cellular polarity, and
regulate the passage of nutrients, solutes and microorganisms across the epithelium.60,61
These junctions are comprised of the tight junction complex, which includes
transmembrane proteins, such as occludin and claudin, and cytosolic adapters such as
zonula occluden 1 (ZO-1), and the adherens junctional complex including cadherins and
-catenin.61
Astrovirus infection alters intestinal barrier permeability via redistribution of
junctional proteins. In vitro HAstV infection of Caco-2 cells induces a drop in
transepithelial electrical resistance (TER) and allows for greater flux of fluorescein
isothiocyanate (FITC)-labeled dextran across the cell monolayer.41 The decrease in TER
and increase in flux is first observed between 16 and 20 hours post-infection (hpi), with
the greatest permeability seen between 36 and 48 hpi, and could be attributed to a
reduction in occludin from the junctional complex and a reduction in F-actin fibers.41
This phenomenon has also been described in vivo. One study of murine astrovirus
(MuAstV) reports an increase intestinal permeability, as measured by orally administered
FITC-labeled dextran crossing the intestinal barrier and reaching the bloodstream.58
Investigations using the turkey poult model present similar results. Infected poults show
increased lumenal-to-serosal flux and disruption of F-actin fibers,59 as well as the
disruption of the localization of the sodium transport proteins NHE3 and SGLT-1.42,59
These findings support the hypothesis that astrovirus may disrupt ionic transport causing
sodium malabsorption and osmotic diarrhea.
Intriguingly, the disruption of barrier integrity associated with astrovirus infection
occurs without active viral replication. Moser et al. found both UV-inactivated HAstV
and recombinant capsid protein increase barrier permeability in Caco-2 cells.41 In
addition, in vivo administration of the recombinant TAstV-2 capsid protein to turkey
poults induces acute diarrhea and relocalization of SGLT-1, comparable to infected
animals.42
More recently studies have focused on defining the cellular tropism for HAstV in
hopes of developing better models to study infection. Initial studies show astrovirus
infects mature intestinal enterocytes at the tips of the villi , macrophages of the lamina
propria, and possibly M cells.62–64 Novel HAstV-VA genotypes are thought to be
neurotropic, as primary astrocytes and SK-N-SH cells are permissive to HAstV-VA1 and
HAstV-4 infection.65 However, viruses from the HAstV-VA and HAstV-MLB clades can
also be propagated in Caco-2, Vero, A549, and Huh7 cell lines as well.66–68 Studies in
human intestinal enteroids reveal that along with enterocytes, HAstV-VA1 infects
intestinal progenitor cells.69 Interestingly, MuAstV is shown to infect actively secreting
goblet cells.70 When mucus production is disrupted, there is a subsequent reduction in
viral infection and shedding.70 Further, the increase in mucus production seen during
MuAstV infection promotes alterations in the gut microbiome that can lead to resistance
of some enteric pathogens.70
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Immune Response
Little is known about the immune response to astrovirus. Multiple studies have
shown infection does not produce overt inflammation unlike many other enteric
pathogens.39,40 Given the acute nature of most astrovirus infections, it is assumed that the
innate immune system is essential for controlling the virus. HAstV replication is sensitive
to the type I interferon (IFN) response, an important part of innate immunity. Two studies
using classical HAstV serotypes showed that IFN-β levels increase after infection and
pretreatment with exogenous type I IFN can reduce replication in Caco-2 cells and
protect epithelial barrier integrity.58,71 Unlike the increase in barrier permeability,
productive replication is required to induce IFN-β in vitro as neither UV-inactivated virus
nor recombinant capsid protein increased IFN-β mRNA levels.58,71 Recently, studies
using HAstV-VA1 in human intestinal enteroids demonstrated a strong type I and III IFN
response is triggered by novel HAstV as well.69 In vivo studies showed that IFNAR
knockout mice, which lack the type I IFN receptor, cannot clear MuAstV infection unlike
wild-type mice.58
Along with inhibiting complement factors as mentioned previously, astrovirus
may modulate the immune response by activating transforming growth factor- (TGF-β),
inducing nitric oxide (NO) production, and impairing macrophage function. In TAstV-2
infected turkey poults active TGF-β levels are elevated compared to uninfected
controls.39 TGF-β is a known immunosuppressive cytokine and may contribute to the
lack of inflammation seen during astrovirus infection. While astrovirus has been shown
to infect macrophages, this infection does not lead to productive replication.72 It does
however decrease macrophage function and viability.73 Also, TAstV-2 infected
macrophages along with infected epithelial produce inducible NO synthase (iNOS)
triggering the production of NO.72,74 Interestingly, that NO production inhibits astrovirus
replication in turkey poults and treatment with NO synthase inhibitors in vitro and in vivo
increased TAstV-2 replication,72 highlighting the role of NO in suppressing astrovirus
infection.
The immediate response of the innate immune system allows for the initial control
of astrovirus and facilitates specific humoral and cell-mediated adaptive responses. More
than 70 percent of healthy adults have detectable HAstV-specific antibodies.75 Nearly 90
percent of children have antibodies to HAstV, so the decrease in the percent of
seropositive adults suggests humoral immunity may wane over time. Volunteer studies
have shown the association between HAstV-specific humoral immunity and disease
outcome. Subjects with HAstV antibodies have less severe symptoms compared to those
without.76,77 Analysis of neutralizing antibodies from several genotype revealed a
quaternary epitope on each side of the dimeric spike domain necessary for
neutralization.78 These studies will help inform decisions for future vaccine development
if a vaccine is ever needed.
In respect to cell-mediated adaptive response, T cells are also believed to be
necessary for viral clearance. In a challenge of biopsied tissue from the small intestine of
healthy adults, CD4+ T cells specific for HAstV were found to reside in the small
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intestine.79 Recent MuAstV research has shown Rag1 knockout mice, which lack B and T
cells, experience prolonged viral shedding in their feces compared to their wild-type
counterparts.80 Rag1 knockout mice also exhibit higher viral titers in the intestines,
mesenteric lymph nodes, spleen, liver, and kidneys, demonstrating the importance of B
and T cells in preventing systemic spread of astrovirus.
Disease
Clinical Features
Volunteer studies confirmed that astrovirus is transmitted via the fecal-oral
route.76,77 We now know the virus can be transmitted through contaminated food, water,
and fomites as well as human-to-human, and is a common nosocomial infection.
Human Disease
HAstV infection typically manifests as watery diarrhea that last 2 to 4 days,
although fever, headaches, abdominal pain and anorexia can also occur.81–83 However,
healthy individuals with HAstV infection may not present with any symptoms.84 It is
thought that a large proportion of HAstV infections are asymptomatic,85 which may be
attributed to immunity from previous exposure.76,77,86
While in healthy individuals HAstV infections are quite mild, increasing reports
indicate in the immunocompromised population, HAstV infections are associated with
severe symptoms and extra-gastrointestinal dissemination.87 The first report suggesting
HAstV to be the causative agent of encephalitis and meningitis was in the 2010 case of a
15-year old boy with X-linked agammaglobulinemia.88 Virus specific primers were
unable to detect the responsible pathogen; however, next-generation sequencing (NGS)
identified HAstV-VA1 in the biopsy samples from the patient. Subsequently, nine other
cases have reported encephalitis and meningitis in association with HAstV infection89–96
(Table 1-1). These cases have primarily been in immunocompromised patients, but two
cases were in immunocompetent individuals, and in eight of the ten cases, a novel HAstV
genotype was identified as the causative agent. These reports demonstrate that HAstV
genotypes can cause severe neurologic symptoms rather than just mild diarrhea,
highlighting the need for extensive research into astrovirus pathogenesis. Especially now
that epidemiological studies show infections caused by novel HAstV genotypes are not as
rare as once thought.97
Animal Disease
Similar to infection in humans, diarrhea is the main symptom of astrovirus
infection in animal species including calves and cattle,98–100 lambs,62,63 turkeys,101–105
chickens,106,107 piglets,108 and dogs,109 among many others.110 Likewise, asymptomatic
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Table 1-1.
Age/Sex
15y/M

Reports of HAstV Detected in Cases of Meningitis or Encephalitis.
Underlying
Conditions

Presentation

Site(s) of
Detection

X-linked
agammaglobulinemia
SCID, gamma C deficient,
post-allogeneic HSCT

Encephalitis

Brain

Encephalitis,
MOF

1.5y/M

Post-allogeneic HSCT

Encephalitis

Brain, heart, lung,
spleen, bone marrow,
kidney, small intestine,
stool, plasma
Brain

42y/M

CLL, post-allogeneic
HSCT
X-linked
agammaglobulinemia
Congenital aplastic
anemia, post-allogeneic
HSCT
None

Encephalitis

Brain, CSF

Encephalitis

Brain

AML, post-allogeneic
HSCT
AML, post-allogeneic
HSCT
Immunocompetent,
generalized seizures

3mo/M

14y/M
4y/M

21y/F
37y/M
8mo/F
16mo/F

Genotype
HAstV-VA
/HMO clade
HAstV-4

Hospitalization
Duration &
Outcome
71 d, Death
17 d, Death

HAstV-VA1
/HMO-C
HAstV-VA1
/HMO-C
HAstV-VA1
/HMO-C
HAstV-MLB1

9 mo, Death

HAstV-MLB2

10 d, Recovered

Meningitis

CSF, anus, urine,
plasma
CSF, plasma, stool

HAstV-MLB2

15 mo, Death

Encephalitis

Brain

196 d, Death

Encephalitis

CSF, stool

HAstV-VA1
/HMO-C
HAstV-1

Encephalopathy CSF, stool, serum,
urine, throat
Meningitis

7.5 mo, Death
>9 mo,
Recovered
19 d, Recovered

9 d, Recovered

Reference(s)
Quan et al.
201088
Wunderli et al.
201189
Brown et al.
201592
Naccache et al.
201593
Fremond et al.
201593
Sato et al.
201691
Cordey et al.
201690
Cordey et al.
201690
Lum et al.
201695
Koukou et al.
201996

Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CSF, cerebrospinal fluid; d, day; F, female;
HSCT, hematopoietic stem cell transplant; M, male; mo, month; MOF, multiple organ failure; ND, not determined; SCID, severe
combined immunodeficiency; y, year.
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infections in animals have also been reported.98,108,111,112 However, other symptoms not
associated with the gastrointestinal tract have been described in certain animal species.
Chicken astrovirus (CAstV) infection in broiler chicks is associated with the hatchery
diseases runting-stunting syndrome (RSS) and “white chicks” condition.113–116 Both of
these ailments present with small hatch size (runting), decreased weight gain (stunting),
increased weakness and mortality, and can be characterized by pale plumage (“white
chick”).117 Similarly, TAstV infections in turkeys is associated with poult enteritis
mortality syndrome (PEMS).118,119 PEMS affects young turkeys and is characterized by
diarrhea, dehydration, severely stunted growth, and high mortality.120 Along with these,
encephalitis has been associated with astrovirus infection in mink, cows, and sheep.121–125
More recently, porcine astrovirus type 3 (PAstV-3) was detected in tissues from CNS of
pigs suffering a neurologic disorder that had symptoms ranging from hind limb weakness
to quadriplegia and occasional convulsions.126
Until recently, paradigm suggested that astrovirus infections were speciesspecific. However, several avian astroviruses share genetic characteristics indicating that
transmission events between species may occur often.127 Additionally, there is evidence
of cross-species infection or transmission between humans and animals. One study found
individuals who work in close contact with poultry are three times more likely to have
antibodies to TAstV-2, than individuals without contact with poultry.128Another study has
shown evidence of both mammalian and avian astrovirus genotypes in non-human
primate fecal samples, as well as HAstV-specific antibodies in plasma samples.129 These
studies suggest astrovirus may not be species specific as once thought; however, it
remains to be seen if infection with cross-species strains would cause symptoms of
disease.
Diagnosis
Originally, HAstV was identified by electron microscopy in positive stool
samples.1,3,130 In the 1990’s, the first RT-PCR and enzyme-linked immunosorbent assays
(ELISA) were developed for detection and typing of HAstV,131–133 making diagnosis
much less laborious and time consuming. Now, several multiplexed real-time RT-PCR
methods exist for quick screening of stool samples for HAstV and additional enteric
viruses, most commonly adenovirus, norovirus, rotavirus and sapovirus.134 At the present
time, only one multiplexed real-time RT-PCR assay to accurately detects HAstV-1–8,
HAstV-MLB1, and HAstV-VA2.135 Unfortunately, due to limited availability of genome
sequences through public databases, development of a real-time RT-PCR methods to
detect all 16 of the known HAstV serotypes has been slow. This is a critical public health
need for researchers in order to improve surveillance efforts and more accurately assess
prevalence.
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Epidemiology
Classical HAstV
Classical HAstV infections are overwhelmingly an affliction of the pediatric
population.136–138 The typical age range of infection is newborn to 5 years,139–142 with up
to 90 percent of children ages 5 years and older having detectable HAstV-specific
antibodies.83,143,144 However, the elderly and immunocompromised are also at risk of
infection.97,145–148 While less common, cases of HAstV infection in healthy adults have
been reported.149–151 Although there happens to be higher incidence of infection in winter,
possibly due to enhanced stability in colder temperatures, HAstV circulates year-round
with infections reported in summer months.152
Classical HAstV infection is thought to be associated with 2 to 9 percent of all
acute, non-bacterial diarrhea in children.110 While incidence of infection decreases with
age, HAstV-1 and HAstV-5 were associated with diarrheal outbreaks in elderly care
facilities.153,154 As of 2013, the mean incidence of HAstV infection was 11 percent
globally, with 7 percent incidence in rural areas and 23 percent in urban areas.155
Incidence tends to be higher in non-developed countries, likely due to poor sanitation and
water treatment methods. Statistics on HAstV infections are significantly affected by
underreporting and asymptomatic cases. Fortunately, the increase in sensitivity of realtime RT-PCR has allowed for more asymptomatic HAstV infections to be detected.156–158
Using more sensitive screening, the rate of HAstV positivity in asymptomatic children is
thought to be roughly 4 percent.152 While the incidence of each of the classical serotypes
differs depending on geographic location, HAstV-1 is the predominant serotype
circulating around the world.83,84,142,159–163 Over the past four decades, the incidence of
HAstV infection has been decreasing from 22 percent in the 1980s to about 5 percent in
the 2000s.155 One hypothesis for this decrease is that novel HAstV genotypes could be
outcompeting the classical genotypes, since reports have shown their prevalence is on the
rise.
Novel HAstV
The link between the MLB and VA clades of HAstV and clinical disease is still
somewhat unclear, making accurate reporting even more difficult compared to classical
genotypes. Reports have exhibited this in the drastic differences in prevalence from one
geographic location to another.87 The most recent review of novel HAstV prevalence,
reports an overall positivity rate 1.5 percent lower than the prevalence of classic HAstV
genotypes.87 In a study of immunocompromised pediatric oncology patients, 50 percent
of samples were positive for HAstV-1; HAstV-VA2 and HAstV-MLB1 were detected in
21 percent and 13 percent of samples, respectively.97 However, a study conducted in
Japan in 2016, found a positivity rate for HAstV-MLB of 10.6 percent, more than double
that of classic HAstV at 5.1 percent.164 Although most reports generally describe a low
prevalence of novel HAstV, their seroprevalence is surprisingly high. Studies in the US
have reported the seropositivity for HAstV-MLB1 to be 86 percent165 and HAstV-VA1 to
be 65 percent,166 indicating a large portion of the population have been infected with
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these viruses in their lifetime. The huge discrepancy between reported prevalence and
seroprevalence again suggests that many RT-PCR screening methods are unable to detect
all members of the HAstV-VA and HAstV-MLB clades resulting in skewed statistics.
Treatment and Prevention
To date, there is no vaccine or widely accepted treatments for HAstV infection.
This is partially due to the relatively mild symptoms of HAstV infection, which typically
resolve without medical intervention. If treatment is necessary, it is generally only to
alleviate symptoms. HAstV-induced diarrhea can cause dehydration and therefore may
require oral or intravenous fluid administration. Administration of intravenous IgG
(IVIG) has been proposed in cases of severe disease in immunocompromised patients,167
but the efficacy of such a treatment needs further investigation.
As there are no vaccines for astrovirus, the most effective method of prevention is
decontamination of fomites and water. Many healthcare facilities regularly use 70 to 90
percent ethanol to disinfect surfaces; however, this treatment is ineffective at completely
eliminating astrovirus.168 Treatment with 90 percent methanol on the other hand, reduces
astrovirus levels to below the limit of detection.118,168 Astrovirus is an incredibly robust
virus that is resistant to many detergents, lipid and chlorine solvents and even to pH as
low as 3.118 Temperature modulation also has very little effect on astrovirus. It can
remain infectious at low temperatures up to ten years,169 and heating the virus at 60°C for
10 minutes did not affect infectivity.118 However, one study has shown that overnight
treatment with 0.3 percent formaldehyde and a 30 minute treatment with 1.5 percent
Virkon S, a peroxymonosulfate, can fully inactivate the virus.118
Astrovirus has been detected in environmental water samples170,171 and shown to
persist in drinking water,172 showing that contaminated water poses a significant threat to
spread astrovirus infection. Typical treatment for drinking water involves disinfection
with chlorine or chloramine. Astrovirus infectivity has been shown to be significantly
decreased by 1mg/L free chlorine for 2 hours.172 However, in areas with poor water
sanitation, astrovirus infection will remain a problem.173,174
Summary
In conclusion, significant progress has been made in the past two decades
although there is still much to be learned about astrovirus. The high seroprevalence of
HAstV-MLB and HAstV-VA genotypes show that these astrovirus infections are more
common than was once thought. Along with the discovery of these novel HAstV
genotypes, researchers have developed a greater appreciation for the virus to spread
systemically and cause encephalitis especially in immunocompromised hosts. In addition,
the need for antivirals to treat these severe cases has been recognized.
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It has also become clear that astrovirus causes disease in an unconventional way.
Rather than causing inflammation of the gastrointestinal tract or inducing apoptosis,
astrovirus disrupts tight junctions, disrupting barrier integrity, and possibly causing
diarrhea. We hypothesize astrovirus induced barrier permeability and disruption of tight
junctions is just the beginning of a more complex process called epithelial-mesenchymal
transition (EMT). My work will determine if astrovirus is prompting EMT and
characterize the mechanism of this process.
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CHAPTER 2.

EPITHELIAL-MESENCHYMAL TRANSITION
Overview

Epithelial and mesenchymal cells serve different roles in the body. As such, these
cells have vastly different phenotypes and gene signatures. Epithelial cells share
specialized contacts with neighboring cells to form regulated barriers. These contacts are
comprised of tight junctions, adherens junctions, desmosomes, and gap junctions
(Figure 2-1). Epithelial cells are also characterized by apical–basolateral polarization,
which is defined by the localized distribution of adhesion molecules especially cadherins
and certain integrins, the organization of cell–cell junctions as a continuous adhesion belt,
the polarized organization of the actin cytoskeleton, and the connection of extracellular
matrix at the basal surface175. While epithelial cells can become motile and release
contacts from their neighboring cell, under normal conditions these cells usually do not
detach from the epithelial layer. Conversely, mesenchymal cells are highly motile and
lack organization into layers and apical-basolateral polarization. They have spindleshaped, fibroblast-like morphology, only contact neighboring cells focally, and rarely
contact the basal lamina.
Epithelial and mesenchymal cells do share inherent plasticity that allows these
cells to switch between one another through a biological process known as epithelialmesenchymal transition (EMT). This process involves extensive, transcriptionally
regulated phenotypic changes that include the loss of cell-cell adhesion and of cell
polarity, and the gain of migratory and invasive properties. EMT has been shown to
induce stem cell properties176,177, prevent apoptosis and senescence178–180, and contribute
to immunosuppression181. With these qualities, EMT is essential in the development and
differentiation of tissues and organs but can negatively contribute to organ fibrosis and
the initiation of metastases.
Phenotypic and Genetic Changes
The first steps of EMT are the disassembly of the epithelial cell-cell junctional
complexes. Upon induction of EMT, junctional proteins are relocalized and/or degraded.
Tight junctional disruption is characterized by decreased claudin and occludin expression
and the dissociation of zonula occludens 1 (ZO-1) from the cell periphery. This is
accompanied by the down-regulation and subsequent loss of expression of the epithelial
adherens junction protein, cadherin (E-cadherin), which is considered a crucial step in the
progression of EMT.182 This disruption of junctional proteins results in a reorganization
of the actin cytoskeleton and loss of apical-basal polarity. The repression of epithelial
genes, such as tight junctions, is subsequently followed by the activation of mesenchymal
genes like vimentin, fibronectin, and N-cadherin.183 These genetic changes associated
with EMT are regulated by families of transcription factors including Snail, zinc finger Ebox-binding homeobox (ZEB), and Twist.183 When the epithelial actin cytoskeletal
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Figure 2-1. Organization of Cellular Junction Complex.
In the intestinal epithelium, neighboring cells form regulated cellular junction complexes
to create an epithelial barrier. From the apical portion of the cell that is exposed to the
lumen to the basal extracellular matrix, the cellular junction complex is composed of tight
junctions, adherens junctions, and desmosomes.
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structure reorganizes, cells can acquire motility and invasive capacities by forming
lamellipodia, filopodia, and invadopodia and by expression matrix metalloproteinases
(MMP) that can degrade extracellular matrix proteins. Figure 2-2 gives an overview of
the changes that occur during EMT.
Induction and Regulation
There are several families of transcription factors that can induce EMT, including
the zinc finger binding transcription factors Snail1 and Snail2,184–186 the basic helix-loophelix (bHLH) factors like ZEB1187 and ZEB2,188 and Twist,189 in addition to a T cell
factor (TCF) known as lymphoid enhancer binding factor-1 (LEF-1).190,191 These EMTinducing transcription factors can be activated by various extracellular stimuli and
mediated through a number of signaling pathways including transforming growth factorbeta (TGF-), bone morphogenetic protein (BMP), epidermal growth factor (EGF),
fibroblast growth factor (FGF), Wnt, Hedgehog (HH), Notch, and integrins. Because
signals mediated by these pathways are transduced via intracellular kinase cascades, there
can be extensive crosstalk between pathways leading to a common endpoint. Once
activated, the transcription factors bind to the promoter of cell adhesion genes to block
their transcription and initiate EMT.
Transcription Factors
Snail Family
Two of the Snail family of transcription factors, Snail1 (Snail) and Snail2 (Slug),
are key repressors involved in EMT. Snail1 and Snail2 are zinc-finger binding
transcription factors and function by sequence-specific binding to the major groove of
DNA.192 The consensus binding site for Snail proteins, CAGGTG,184,185,193,194 is also
known as an enhancer box (E-box). This is the same binding motif used by bHLH
transcription factors.195 This suggests Snail transcription factors may compete with bHLH
factors for binding. Once bound to the E-box, the Snail proteins act as transcriptional
repressors. The promoter of CDH1, which encodes E-cadherin, contains two adjacent E
box consensus sequences where Snail proteins can bind to repress its transcription.196
These transcription factors achieve repression by recruiting both repressor and chromatin
remodeling complexes.197–199
While E-cadherin is the only identified target of the Snail family, studies have
produced other potential genes that may be directly or indirectly regulated.
Overexpression of Snail results in the down regulation of other epithelial markers, like
desmoplakin,184 Muc-1200,201 and cytokeratin-18.202 In addition, mesenchymal markers
like vimentin and fibronectin become upregulated and reorganized.184
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Figure 2-2. Epithelial-Mesenchymal Transition (EMT) Characteristics.
EMT is the biological process in which polarized epithelial cells to undergo genetic and
phenotypic in order to switch to mesenchymal cells. This process is characterized by cells
losing their cell polarity and cell-cell adhesion and gain migratory and invasive properties
common to mesenchymal cells.
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ZEB Family
The ZEB protein family are bHLH and consist of two members, ZEB1 and ZEB2.
Like the Snail family, bind to E-box regions of the CDH1 promoter to repress its
transcription.203,204 In the nucleus, ZEB proteins mainly interact with activated SMAD
proteins and recruit either the corepressor C-terminal binding protein (CtBP) or histone
deacetylase complexes.205–208 Exogenous ZEB expression in mammary epithelial cells
induces the disruption of adherens junctions, through the suppression of E-cadherin, as
well as plakophilin-2 and ZO-3.203,204 Also, cells transfected with ZEB1upregulate genes
encoding matrix metalloproteinases (MMP),209 suggesting ZEB proteins are involved
with extracellular matrix (ECM) remodeling associated with EMT.
Twist Family
Another group of bHLH proteins associated with EMT is the Twist family of
transcription factors made up of Twist1 and Twist 2. As with Snail and ZEB, Twist binds
to the promoter region of CDH1 at the E box regions. There it recruits methyltransferases
to facilitate H4K20 monomethylation, which represses the E-cadherin promoter but
activates the N-cadherin promoter.210 However, this regulation of transcription is not
dependent on Twist alone. Twist has been shown to bind the SNAI2 promoter because
Snail2 expression is essential for Twist1-induced invasion and metastasis.211
The interplay between Twist and Snail1 are also necessary for the induction of
ZEB. The transfection of both Twist and Snail are needed for the optimal transcription of
ZEB1.212 The expression of Snail1 and Twist are also dependent on each other. Down
regulation of Twist has been shown to suppress Snail1, and Snail1 is necessary for the
increase in Twist protein and upregulation of Twist1 transcript.212 These results indicate
the co-regulatory function each of these transcription factor families play in the induction
of EMT.
Signaling Pathways
While there are many different extracellular cues inducing EMT, there is
significant crosstalk between the signaling cascades. This section highlights the best
characterized signaling inducers of EMT (Figure 2-3).
TGF-β
TGF-β signaling is considered the hallmark inducer of EMT. TGF‐β is a
pleiotropic cytokine involved in cell proliferation, cell differentiation, apoptosis, matrix
accumulation and tumor migration.213 Signaling is activated by the TGF-β superfamily of
ligands, which include three isoforms of TGF-β (TGF-β1-3) and six isoforms of BMP
(BMP-2–7) among other ligands.183 TGF-β signaling occurs through the binding of a
ligand to the tetrameric receptor complex composed of type I and type II TGF-β
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Figure 2-3. EMT Signaling Pathways.
EMT can be triggered by a number of different extracellular cues that can then be relayed
via signaling pathways including transforming growth factor- β (TGF-β), bone
morphogenic protein (BMP), receptor tyrosine kinase (RTK), Wnt, Notch, and
Hedgehog. The result of these signaling cascades is the upregulation of the transcription
factors Snail1/2, zinc finger E-box-binding homeobox (ZEB) 1/2, Twist and lymphoid
enhancer binding factor-1 (LEF-1). The transcription factors act as transcriptional
repressors to induce EMT by inhibiting the transcription of epithelial markers like
claudins, E-cadherin, occludin, and zonula occludens-1 (ZO-1). There are known
pathways that can inhibit EMT induction, for instance GSK3β targets β-catenin for
degradation, thereby inhibiting it interaction with LEF-1. In addition, the miR-200 family
of microRNAs directly inhibits the translation of ZEB.
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receptors.213 Once bound, the type II receptor phosphorylates the type I receptor, which in
turn phosphorylates an intracellular signaling effector.213 Following activation, TGF-induced EMT can proceed through SMAD dependent or independent signaling
transduction.
Typically, SMADs are the main intracellular signaling effectors for TGF-
signaling transduction. The phosphorylation of the type I TGF- receptor creates a
docking site for the receptor regulated SMADs, SMAD2 and SMAD3. The
phosphorylation of SMAD2/3 recruits SMAD4, creating the functionally active SMAD
complex which can translocate to the nucleus.214 Once in the nucleus, the SMAD
complex binds the DNA motif CAGAC to transcriptionally regulate downstream
genes.215 The SMAD complex can bind to the promoter of SNAI1 to induce the
expression of Snail1. Subsequently, Snail1 can complex with SMADs to suppress the
Snail targets, occludin and E-cadherin.216 ZEB transcription factors are also known to
bind to SMAD to regulate the expression of Snail1, Snail2 and Twist.217
Besides SMAD-dependent signaling, TGF-β can activate signaling through Rholike GTPases, which control organization of the actin cytoskeleton and cell
mobility.218,219 TGF-β signaling rapidly activates RhoA and Rho-associated protein
kinase (ROCK) in cells undergoing EMT.220–222 Conversely, TGF- β has been found to
down-regulate RhoA as well. Par6, a polarity complex protein, binds to the type 1 TGF-β
receptor. When the receptor is activated Par6 is phosphorylated and recruits Smurf1, an
E3 ubiquitin ligase.223 Together the Par6-Smurf1 complex target RhoA for ubiquitination,
leading to a loss of cell junctions associated with TGF--induced EMT.223 Along with
RhoA, TGF- can activate Cdc42, a GTPase highly involved in the formation of
lamellipodia and filopodia.224,225 In addition to Rho-like GTPases, TGF-β receptors have
kinase activity and therefore can activate mitogen-activated protein kinase/extrcellular
signal regulated kinase (MAPK/ERK), c-Jun N-terminal kinases (JNK)-p38 MAPK, and
phosphatidylinositol 3-kinase (PI3K)-Akt.226–234 These signaling pathways are similarly
activated by the RTKs and so will be described in detail in the next section.
Receptor Tyrosine Kinase
As the name implies, RTKs are transmembrane-spanning receptors with
intracellular C-terminal catalytic domains that have kinase activity.235 A number of
growth factors and cytokines including epidermal growth factor (EGF), fibroblast growth
factor (FGF), insulin-like growth factor (IGF), vascular endothelial growth factor
(VEGF), and platelet-derived growth factor (PDGF) are known to signal through
RTKs.235 As RTK signaling is essential for embryonic development and tissue
regeneration and tumorigenesis, it is highly involved in EMT. EGF signaling through
MAPK/ERK results in the upregulation of Snail and Twist, the loss of E-cadherin, and
the activation of MMPs.236–238 In tubular epithelial cells, FGF-2 induces EMT in by
upregulating vimentin and fibroblast specific protein-1(FSP-1) and inducing the activity
of MMP-2.239 In a separate study, FGF-2 was shown to signal via Rho-GTPases and
PI3K to induce cytoskeletal changes.240 IGF has been reported to signal through NF-B,
MAPK/ERK, and PI3K-Akt to induce EMT.241–243 NF-B signaling via IGF increases
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Snail expression,241 while MAPK/ERK signaling increases ZEB expression.242 In breast
cancer cells, VEGF inhibits glycogen synthase kinase 3 (GSK3) and induces the
upregulation of Snail.244 Consequently, Snail1 increases the expression of VEGF creating
a positive feedback loop.245,246 In embryogenesis, PDGF regulates the expression
of CDH2, which encodes N-cadherin, in mesoderm through the PI3K pathway.247
Wnt Signaling
The Wnt signaling cascade begins with Wnt proteins binding to a Frizzled
receptor, a family of G-protein coupled receptors (GPCR) and a lipoprotein receptorrelated protein (LRP) co-receptor.248 This signaling pathway inhibits glycogen synthase
kinase 3β (GSK3β).249 In its normal role, GSK3β phosphorylates β-catenin to mark it for
ubiquitination and ultimately degradation.250 By inhibiting GSK3β, Wnt signaling
prevents the degradation of β-catenin and allows it to regulate gene transcription. In the
nucleus, β-catenin recruits LEF-1 forming a complex that binds to the promoter of CDH1
and suppresses expression of E-cadherin.251 The inhibition of GSK3β also has direct
effects on Snail by preventing its ubiquitination and consequently promoting EMT
associated gene regulation.252
Wnt signaling is essential in the development of vertebrates. Canonical WNT
signaling is required to generate neural crest precursors,253 while Wnt3 knockout mice do
not develop proper anterior-posterior neural patterning.254 Aberrant Wnt signaling, has
also been reported in many different cancer types including prostate,255 breast,256
colorectal,257 and liver cancers.258
Notch
Notch signaling is highly involved in developmental EMT. Upon binding to the
Notch receptor by the ligands, Jagged or Delta-like, the Notch intracellular domain
(NICD) is cleaved by ADAM-family metalloprotease and -secretase and traffics into the
nuclease to regulate gene expression.259 The NICD can bind to the SNAI1 promoter to
upregulate the expression of Snail1.260 In addition, NICD can interact with hypoxiainducible factor 1α (HIF-1) to upregulate lysyl oxidase (LOX), which can then stabilize
Snail1 protein.260 Interaction of Notch with Snail2 is necessary for Notch-mediated
repression of E-cadherin, activation of -catenin, and resistance to anoikis.261 In
development, Notch and TGF- cooperate to activate Snail2 in endothelial cells during
morphogenesis of the cardiac cushion.262 Inhibition of Notch in lung cancer cells showed
a partial reversal of EMT and decreased invasiveness.263
Hedgehog
The HH family ligands comprised of Sonic Hedgehog (SHH), Indian Hedgehog,
and Desert Hedgehog are important regulators of embryogenesis. These ligands bind to
the receptors patched homolog 1 (PTCH1) and PTCH2, However, signaling is not
transduced via PTCH receptors, instead binding of HH to PTCH releases the seventransmembrane receptor Smoothened (Smo) which initiates an intracellular signaling.264
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Smo signaling activates Gli transcription factors, which upregulate target genes such as
PTCH1and SNAI1.265 Reports have also shown, HH signaling induces TGF-β1 secretion
to promote motility and invasion of gastric cancer cells.266
During development, SHH is expressed in the notochord and the neural tube 267. It
is also required for the survival of myogenic and chondrogenic cell lineages which give
rise to the muscle and cartilage tissues.268 In rat kidney cells, the exogenous expression of
Gli1 upregulates Snail1 expression and Ectopic expression of Gli1 in rat kidney epithelial
cells induces Snail1 expression, and the subsequent the reduction of E-cadherin
expression.265
MicroRNA
Recent studies have revealed along with traditional signaling pathways,
microRNAs can regulate EMT as well. MicroRNAs (miRNA, miR) are small non-coding
RNAs that are approximately 22 nucleotides long. By binding to the 3’ untranslated
region (UTR) of specific gene transcripts, miRNAs inhibit the translation of that protein
(Figure 2-4).269 To date, there are more than seventy different miRNAs reported to be
involved in EMT regulation.269–271 In particular, miRNAs have been shown to target the
transcription factors responsible for the induction of EMT.272 The miR-220 family
members, miR-200a, miR-200b, miR-200c, miR-141, and miR-429, directly target
ZEB1/2 to inhibit their expression.273–276 In addition, Snail is targeted by members of the
miR-30 and miR-34 family as well as miR-203 inhibiting EMT.277–280 However, not all
miRNAs inhibit EMT, miR-9 is a putative oncogene that directly targets CDH1 thus
promoting EMT.281–283 Additionally, miR-373 and miR-520c target the cell surface
adhesion molecule, CD44, to stimulate tumor invasion.284
Types of EMT
EMT is an expansive topic. To parse out common signaling pathways and
transcriptional regulation, researchers have divided EMT into three subtypes.
Type 1: Embryogenesis
EMT was initially identified in embryos as the fundamental process for the
generation of tissues and organs. Type 1 EMT involves primitive epithelial cells
transitioning to motile mesenchymal cells as part of gastrulation and generating the
neural crest.285 During embryogenesis, a fertilized egg will go through gastrulation to
generate a primitive streak.286 From the primitive streak arises the three primary germ
layers that will eventually generate all tissues and organs in the body. In order to form
different tissues, cells of the germ layers must undergo programmed genetic and
phenotypic changes orchestrated by specific signaling proteins in a process now known
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Figure 2-4. MicroRNA Processing and Function.
MicroRNAs (miRNA) are small non-coding RNAs that decrease the expression of
mRNAs with sequence complementary to the miRNA. Following transcription, the primRNA are processed by Drosha into a pre-miRNA. Once transported out of the nucleus,
the pre-miRNA, is further process by Dicer into mature miRNA. The miRNA can then
associate with RISC proteins to bind mRNA, leading to a number of consequences
including induced decapping or deadenyltion, altered cap protein binding, reduced
ribosome occupancy, and sequestration of the mRNA from translational machinery
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as EMT.175 The resulting mesenchymal cells travel to their intended destination and
through the reversal process MET, mesenchymal-epithelial transition, begin early
organogenesis.285
Type 1 EMT is dependent on canonical Wnt, FGF, and BMP signaling. Embryos
with Wnt3 knocked out are incapable of undergoing the EMT necessary for
gastrulation.254 Wnt8c is also necessary for the formation of the primitive streak, in fact
over expression of Wnt8c leads to the formation of duplicate primitive streaks.287,288 FGF
signaling has been shown to work in unison with Wnt signaling, inducing Snail and thus
repressing E-cadherin.289 In further developmental stages of embryogenesis, BMP
signaling induces the migratory state necessary to form the neural crest.290,291 Subsequent
combinations of signaling pathways and regulatory transcription factors associated with
EMT are activated to continue the full development of the growing embryo.292
Type 2: Wound Healing
Following injury or chronic inflammation, tissues undergo regeneration and
repair. Type 2 EMT involves the process of epithelial cells switching to fibroblasts in
response to damage. This is a key distinction between type 1 and type 2 EMT, as type 1
EMT yields mesenchymal cells, while type 2 EMT results in resident tissue fibroblasts.285
Along with wound healing, type 2 EMT can also result in tissue fibrosis. Fibroblasts
formed by type 2 EMT can migrate and take up residence in the interstitium where they
are primed to respond to inflammation.292 Tissue injury results in the release of many
growth factors and extracellular cues like TGF-β, PDGF, FGF-2, collagens, and laminins
that can stimulate EMT.239,293,294
The importance of TGF- signaling in the development of fibrosis was shown in
studies using BMP-7, an antagonist TGF-.295–297 BMP-7 can inhibit TGF-- induced
EMT and rescue E-cadherin expression.295,298 In addition, by administering recombinant
BMP-7 to mice with fibrosis, researchers were able to reverse EMT and repair fibrotic
tissue with healthy epithelial cells.298
Type 3: Cancer
Given that EMT is associated with enhanced cellular mobility, it is to be expected
that tumorigenesis is enabled by EMT. Type 3 EMT involves epithelial cancer cells
transitioning to invasive tumor cells in order to circulate through the body and to form
secondary metastases via MET. 299 While EMT appears to drive dissemination of tumor
cells, it must be halted before metastatic colonization can take place.300,301 Interestingly,
many circulating tumor cells express both epithelial and mesenchymal markers,302,303
suggesting the EMT process is active during the dissemination of cancer cells. While
similar signaling pathways are involved in type 3 EMT as type 1 and 2,292,304 it is still
unclear what signals are distinct to type 3 EMT.299
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In addition to gaining migratory properties, cancer cells undergoing EMT exhibit
more aggressive phenotypes, including resistance to chemotherapeutics,305,306 inhibition
of senescence,180,307 and features of stem cells.179,300 It has been reported that following
the induction of EMT, cancer cells express CD44highCD24low which are widely accepted
as stem cell markers.176,308,309 In a study using human mammary cells, induction of EMT
via TGF-β treatment or the overexpression of Snail and Twist resulted in the cells
exhibiting increased self-renewal and ability to form tumors 301
Partial EMT
While it is easy to think of EMT and MET as processes with distinct
mesenchymal or epithelial outcomes, recent research suggests EMT is really a spectrum
with cells displaying both epithelial and mesenchymal characteristics.300,310–312 In this
phenotype cells may express collagen I, vimentin or -SMA, while also retaining loose
cell-cell adhesion proteins. 292 This so called “metastable” or partial EMT has been
reported in association with all 3 types of EMT.313–316 Circulating tumor cells exhibiting a
hybrid epithelial/mesenchymal phenotype have been shown to migrate and invade the
ECM as multicellular clusters.303,317,318 Interestingly, in so cases partial EMT seems to be
the preferred outcome. In a model of kidney fibrosis, renal epithelial cells do not undergo
full EMT, rather they provide signals needed for the differentiation of myofibroblasts.315
Also instead of reverting back to epithelial cells, these cells remain in the interstitium
poised to respond to further inflammation.315 Partial EMT highlights the intricate
regulation of transcriptional activators and suppressors necessary for the induction and
progression of EMT.
Viral-Induced EMT
Relatively few viruses are known to induce signatures of EMT. Hepatitis B virus
(HBV)319, hepatitis C virus (HCV)320, human papilloma virus (HPV)321, Epstein-Barr
virus (EBV)322, Kaposi sarcoma-associated herpes virus (KSHV)323 and cytomegalovirus
(CMV)324,325 have all been shown to drive EMT, which is not surprising given that they
are oncogenic viruses. EMT is thought to initiate metastases and cause hepatocellular
carcinoma326, cervical carcinomas327, and lymphoma326 among other diseases associated
with infection by these viruses. While the signaling pathways utilized by these viruses to
induce EMT are different, it is regulated through the interaction of one or more of their
viral proteins.322,323,328–339 More recently rhinovirus340 and transmitted gastroenteritis
coronavirus (TGEV)341 were shown to induce EMT. The mechanisms leading to EMT
and the role in pathogenesis remains unknown. However, TGF- is implicated as the
main signal transducer for both viruses.340,341
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Research Aims
The overall goal of my studies was to determine the underlying mechanisms(s) of
astrovirus-induced EMT and determine the impact of EMT on astrovirus replication. To
our knowledge, these are amongst the first studies focused on understanding EMT
induced during infection with a non-oncogenic virus and will lead to important new
information on viral-regulated EMT as well as a better understanding of astrovirus
pathogenesis. I hypothesized that human astrovirus activates TGF-β leading to EMT in
Caco-2 intestinal epithelial cells. This hypothesis was tested through the following
specific aims:
Aim 1: Define the Extent of Astrovirus-Induced EMT
Through the use of qRT-PCR, Western blotting analysis and confocal microscopy
of the EMT associated markers occludin, E-cadherin, Snail, Twist, vimentin, and
fibronectin, we characterized the hallmarks of astrovirus-induced EMT in human
intestinal epithelial Caco-2 cells. The hallmarks of EMT that were investigated include:
the loss of epithelial gene expression and dysregulation of cell junctions, the loss of
apical-basal polarity, the activation of mesenchymal genes, and increased expression of
mesenchymal proteins.
Aim 2: Examine the Mechanism(s) for Astrovirus-Induced EMT
Our laboratory has previously shown that the astrovirus capsid protein is
sufficient to cause barrier permeability and has more recently found that astrovirus
infection increased TGF-β activity. The goal of this aim was to determine if astrovirus
replication and/or astrovirus-activated TGF-β are required for EMT induction
The data formed by this project will not only provide fundamental new research
on astrovirus pathogenesis, they will increase our understanding of non-oncogenic
induced EMT. The outcome of these studies will likely lead to an exciting new area of
investigation for non-oncogenic viruses and novel areas of research into the physiology
of the gastrointestinal tract by enteric viruses.
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CHAPTER 3.

MATERIALS AND METHODOLOGY1
Cell Culture Procedure

The human intestinal adenocarcinoma cell line Caco-2 was obtained from ATCC
(HTB-37). The cells were propagated in minimum essential medium (MEM; Corning)
supplemented with 20% fetal bovine serum (FBS; HyClone), GlutaMax-I (Gibco), 1 mM
sodium pyruvate (Gibco), and penicillin-streptomycin (Gibco).
The mink lung epithelial cells (Mv1Lu) used in the PAI assay were obtained from
a collaborator. The cells were propagated in Dulbecco's Modified Eagle Medium
(DMEM; Corning) supplemented with 10% FBS (HyClone) and were maintained under
selective pressure with 0.4mg/ml of G418 (InvivoGen).
The occludin knockdown Caco-2 cells were a generous gift from Dr. Carolyn
Coyne. The cells were propagated in DMEM (Corning) supplemented with 10% FBS and
0.01 mg/ml human transferrin (Sigma).
Reagents and Methods Related to HAstV-Induced EMT
Virus Propagation
HAstV-1 was propagated in Caco-2 cells, and the titers of the virus were
determined on Caco-2 cells by the fluorescent-focus assay as previously described.343 To
UV inactivate the virus, 100 μl of HAstV-1 was subjected to 100 mJ/cm2 with a UV
cross-linker as described previously,41 and inactivation was confirmed by the fluorescentfocus assay.
Immunofluorescent Staining and Confocal Imaging
Briefly, Caco-2 cells were seeded onto glass coverslips (for epithelial and
vimentin staining) or transwells (polarity and SMAD staining). Once confluent, the cells
were infected with HAstV-1 (MOI 10) or mock infected. At various times post-infection,
cells were fixed with 4% paraformaldehyde (for epithelial and vimentin staining) or
100% ice cold methanol (polarity and SMAD staining), and then blocked with 5% normal
goat serum (NGS) in PBS at room temperature for 1 hr. The cells were stained for Ecadherin (33-4000; Invitrogen), occludin (71-1500; Invitrogen), ZO-1 (33-9100 and 617300; Invitrogen), sodium-potassium ATPase (ab167390; abcam), ezrin (MA5-13862;
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Portions of chapter from previously published article; final submission modified with permission.
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Invitrogen), β-catenin (ab32572; abcam), SMAD3 (51-1500; Invitrogen), HAstV
capsid(8e7; DakoCytomation), and vimentin (ab92547; abcam) for 1 hr followed by antimouse IgG-Alexa Fluor 488 or anti-rabbit IgG-Alexa Fluor 555 (Invitrogen) secondary
antibodies and DAPI (4′,6′-diamidino-2-phenylindole; Sigma) in 1% NGS for 30 min at
room temperature. Following staining, coverslips or transwells were mounted onto slides
with Prolong Gold Antifade Mountant (Invitrogen) and sealed. Cells were imaged with a
Nikon TE2000 inverted microscope Images were captured with a Nikon 60x objective
lens using Nikon NIS Elements software.
Western Blotting
Caco-2 cells were mock infected or HAstV-1 (MOI 10) infected, or were treated
with an equal amount of UV-inactivated virus, or mock-infected lysate in MEM as a
negative control. At the indicated times, monolayers were lysed in 100 μl of RIPA buffer
(Abcam) and 1× protease inhibitor cocktail (Pierce) for 15 min at room temperature and
centrifuged at 14,000 × g for 5 min at 4°C. Protein concentrations were determined using
the BCA Protein Assay Kit (Pierce). Equal protein concentrations of the soluble fraction
were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) (4-20%) under reducing conditions. Following transfer to nitrocellulose and
probing for for E-cadherin (33-4000; Invitrogen), occludin (71-1500; Invitrogen), ZO-1
(33-9100; Invitrogen), β-catenin (ab32572; abcam), vimentin (ab92547; abcam), and βactin (A5441; Sigma).The blot was imaged on Licor Odyssey Fc and band densitometry
was measured using Image Studio version 5.2 software.
RT2 Profiler
Briefly, cells were seeded in 6-well plate, mock infected or HAstV-1 (MOI 10)
infected and collected at the indicated time point in TRIzol reagent (Thermo Fisher
Scientific). Then, RNA was isolated according to the manufacturer's instructions. RNA
quality was determined and was reverse transcribed using Qiagen’s RT2 First Strand Kit
(Cat# 330401). The cDNA was used on the real-time RT2 Profiler PCR Array (Cat#.
PAHS-090Z) in combination with RT² SYBR Green qPCR Mastermix (Cat# 330529).
The Ct values were then uploaded on to the data analysis web portal at
http://www.qiagen.com/geneglobe. Samples were assigned to either control or test
groups. The data was normalized based on a manual selection from full panel of
reference genes. The data analysis web portal calculated fold change/regulation using
ΔΔCt method, in which ΔCt is calculated between gene of interest and an average of
reference genes (B2M, HPRT1, and RPLP0), followed by ΔΔCt calculations (ΔCt (Test
Group)-ΔCt (Control Group)). Fold Change was then calculated using 2^ (-ΔΔCt)
formula.
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Quantitative RT-PCR
Caco-2 cells were infected with HAstV-1 or mock infected and RNA extracted at
indicated timepoints using TRIzol (AMbion) according to manufacturer’s specifications.
Then qRT-PCR was performed using the QuantiTect SYBR green kit (Qiagen) primer
assays for OCLN (cat# QT00081844), CDH1 (cat# QT00080143), SNAI1 (cat#
QT00010010), and VIM1 (cat# QT00095795). The resulting Ct values were normalized
to GAPDH (cat# QT00079247). The log transformed ΔΔCt values are reported as fold
changes over untreated.
TGF-β Activity Assay
TGF-β activity was measured using a luciferase reporter cell line, as previously
described.344 Briefly, mink lung epithelial cells (Mv1Lu), stably transfected with a
luciferase reporter construct downstream of the plasminogen activator inhibitor-1 (PAI-1)
promotor, were plated in a 96-well tissue culture plate (2x104). These cells were
inoculated with supernatants (100 μl) taken from HAstV-1 (MOI 10) or mock-infected
Caco-2 cells at various times post-infection and incubated at 37°C for 16-20 hours.
Active TGF-β (R&D Systems) served as a positive control. The inoculum was removed
and the cells washed twice with PBS. Cell lysates were prepared and assayed for
luciferase activity using the Luciferase Assay System (Promega) and imaged on the
Cytation 5 Cell Imaging Multi-Mode Reader (BioTek).
SB431542 and U0126 Treatment
Briefly, 5 × 104 cells were seeded into transwells (3074; Corning), and once
confluent, transferred into serum free media for at least 1 hr. The cells were treated with
10μM SB431542 (Tocris) or U0126 (Promega) 1 hr prior to infection. Then the cells
were infected with HAstV-1 (MOI 5), TGF-β treated (20ng), or mock infected in serum
free media. Following the virus adsorption period of 1hr, the inoculum was removed and
fresh media containing 10μM SB431542 or U0126 was replaced.
Statistical Analysis
Data were analyzed by two-way ANOVA followed by Tukey’s multiple
comparisons test (RT-PCR), ordinary one-way ANOVA followed by a test for trend
(epithelial protein expression), two-tailed student t-test (Na/K ATPase localization), twoway ANOVA followed by Sidak’s multiple comparisons test (TGF-β Activity), ordinary
one-way ANOVA followed by Dunnett’s multiple comparisons test (E-cad expression
with SB431542, UV-inactivated virus, and U0126, and RT-PCR with SB431542 and UVinactivated virus), using GraphPad Prism version 8. Asterisks show statistical
significance as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Reagents and Methods Related to Nitazoxanide
Virus Propagation
Laboratory-adapted human astrovirus stocks (HAstV-1, HAstV-2, HAstV-6, and
HAstV-8) were propagated in Caco-2 cells, and the titers of the viruses were determined
on Caco-2 cells by the fluorescent focus assay (focus-forming units [FFU]) as previously
described.343
Clinical isolates (SJ177.110, SJ60.212, SJ88123.E120, and SJ88027.E259) were
derived from remnant fecal samples submitted for clinical diagnostic testing at St. Jude
Children’s Research Hospital. All samples were deidentified before testing. The St. Jude
Institutional Review Board approved this study with a waiver of consent. All isolates
were propagated in Caco-2 cells. Briefly, a 10 to 20% dilution of stool extract, positive
for HAstV by real-time reverse transcription-PCR (qRT-PCR), was filtered through a
0.22-μm filter. The extract was diluted 1:10 in MEM with 5 μg/ml porcine trypsin before
adsorption onto Caco-2 cell monolayers. Following a 1-h adsorption period at 37°C, the
inoculum was removed and replaced with MEM containing 10 μg/ml porcine trypsin and
0.3% bovine serum albumin (BSA). The titers of the viruses were again determined on
Caco-2 cells by the fluorescent focus assay.343
TAstV-2 stocks were prepared from intestines collected from infected turkey
poults. Briefly, pieces of intestine were suspended in 0.5 ml PBS, homogenized using 2mm zirconium oxide beads (Next Advance) for 4 min (at speed setting 4 in the Next
Advance air cooling bullet blender), and pelleted by centrifugation at 12,000 rpm for 5
min. The supernatant was pooled and filtered through a 0.2-μm filter (fecal filtrate), and
viral copy number was quantified by qRT-PCR.
In Vitro HAstV Infection and NTZ Administration
Briefly, 5 × 104 cells were seeded into 96-well tissue culture plates (Corning), and
after 2 days, the cells were inoculated with virus (HAstV-1 or clinical isolates) in serumfree MEM for 1 h at 37°C, at which time the virus was replaced with MEM containing
0.3% BSA and infection was allowed to proceed until 24 hpi or as described in the figure
legends. For NTZ treatment, NTZ or DMSO (0.3% to 3%) was added to the infection
medium at the concentrations and times described in the figure legends.
Immunofluorescent Staining
Cells were fixed with 100% ice-cold methanol for 15 min and then blocked with
5% normal goat serum (NGS; Gibco) in PBS at room temperature. Cells stained for
astrovirus capsid protein were incubated with HAstV mouse monoclonal antibody 8E7
(2 μg/ml; DakoCytomation), and cells stained for dsRNA were incubated with J2 mouse
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monoclonal antibody (Scicons)345 for 1 h at room temperature. Following incubation with
primary antibody, cells were incubated with anti-mouse IgG labeled with Alexa Fluor
488 (Invitrogen) as the secondary antibody and with DAPI (4′,6′-diamidino-2phenylindole; Sigma) for 30 min at room temperature. Staining was imaged on the EVOS
FL cell imaging system and analyzed using ImageJ 1.50i software.
MTT Cell Viability Assay
Cell viability was tested using an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5diphenyl-2H-tetrazolium bromide] cell proliferation assay kit (Abcam) according to the
manufacturer’s protocol. Briefly, cells were treated with various concentrations of
nitazoxanide in serum-free medium for 24 h. The nitazoxanide-containing medium was
removed and replaced with a 50:50 mixture of MTT reagent and serum-free medium. The
cells were incubated with the mixture at 37°C for 3 h. Following incubation, an MTT
solvent solution was added and the plate was placed on an orbital shaker for 15 min. The
absorbance was then measured as optical density at 595 nm (OD595). Cell viability was
calculated as the percentage compared to the cell viability in nontreated cells.
IFN qRT-PCR
Caco-2 cells were treated with 2.5 μM NTZ or not treated, and RNA extracted at
2 and 4 h posttreatment using TRIzol (Ambion) according to the manufacturer’s
specifications. Then, qRT-PCR was performed using the QuantiTect SYBR green kit
(Qiagen) primer assays for IFNα1 (catalog number QT00201964; Qiagen), IFNβ1
(catalog number QT00203763; Qiagen), and IFNλ1 (catalog number QT00222495;
Qiagen). The resulting cycle threshold (Ct) values were normalized to the value for
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (catalog number QT00079247;
Qiagen). The log-transformed ΔΔCt values are reported as fold changes over the values
for untreated cells.
Animals and NTZ Treatment
Broad-breasted white turkey poults were obtained from a commercial hatchery.
Five-day-old poults were randomly assigned to groups (n = 6 per group) and housed in
individual, temperature-controlled Horsfall units with HEPA-filtered inlet and exhaust air
valves, where they were given free access to water and routine turkey starter feed. Poults
were orally inoculated with 500 μl of TAstV-2 intestinal filtrate, containing
approximately 1012 to 1013 genome copies, or PBS alone. Stool samples from individual
birds were scored from 1 to 4. Scoring was performed daily post-infection. Scores of 3
(liquid or loose stool with some undigested food or solid material) and 4 (watery stool
with no solids present) were defined as diarrhea, in accordance with previously published
work from Meliopoulos et al.42
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For NTZ treatment, poults were orally administered 100 mg/kg nitazoxanide in
500 μl of ultrapure water. Administration of NTZ was carried out for 4 days prior to
infection and 3 days post-infection.
Turkey Astrovirus qRT-PCR Assay
TAstV-2 genome copies were determined as previously described.42 Briefly, viral
RNA was isolated from 10% stool by using the MagMAX-96 avian influenza
(AI)/Newcastle disease (ND) viral RNA isolation kit (Applied Biosystems) according to
the manufacturer’s protocol. PCR was performed on 3 μl of each sample using TaqMan
fast virus 1-step master mix (Applied Biosciences) with 600 nM forward primer
5′GACTGAAATAAGGTCTGCACAGGT, 600 nM reverse primer
5′AACCTGCGAACCCTGCG, and 200 nM probe 6-carboxyfluorescein (6FAM)ATGGACCCCCTTTTTCGGCGG-BHQ1 (black hole quencher 1) under the following
conditions: 50°C for 5 min and 95°C for 20 s, followed by 45 cycles with one cycle
consisting of 95°C for 3 s and 60°C for 30 s on a Bio-Rad CFX96 real-time PCR
detection system. The number of genome copies/μl of total RNA was determined using a
standard curve generated from a synthesized TAstV-2 DNA sequence, comprising
nucleotides 4001 to 4201, with a known copy number (calculated using Thermo Fisher
Scientific DNA Copy Number and Dilution Calculator). Log10 dilutions of the
synthesized TAstV-2 DNA were used for qRT-PCR as described above.
Statistical Analysis
Data were analyzed by ordinary one-way analysis of variance (ANOVA) (EC50
and MTT assay), multiple t test (capsid and dsRNA staining time course), and two-way
ANOVA (turkey stool titers) using GraphPad Prism version 8.
Transepithelial Electrical Resistance (TER)
Caco-2 cells were plated at a density of 5 × 104 cells/well on 6.5 mm
semipermeable (0.4μm) tissue culture inserts (3470; Corning) and incubated for 3 or 4
days until the TER reached approximately 1,000 Ω·cm2. Cells were then transferred to
serum free media at least 1 hr prior to treatment. The cells were treated with UVinactivates supernatant or infected with HAstV-1 (MOI 10), and TER levels were
measured continuously every 15 min for 24 hours using a cellZscope+ voltohmmeter
(nanoAnalytics). Results are presented as percentages of the insert's initial TER reading
(time zero) relative to mock infection.
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Astrovirus Capsid ELISA
96-well ELISA plates (9018; Corning) were coated with 5 ug/ml HAstV capsid
protein, purified whole HAstV-VA1 virus or BSA in PBS. The coated plates were
allowed to incubate at 4°C overnight. The plates were then washed 3x with at least 200 ul
PBS-0.01% tween (PBST). Following washing, the plates were blocked with 4% BSA in
PBST for 1 hr at room temperature. After blocking, the plates were washed as before and
then sequential dilutions of IVIG were plated in 1% BSA in PBST. This was allowed to
incubate 1-2 hr at room temperature. Following incubation, any free IVIG was washed
away as previously described. Then anti-human secondary antibody conjugated to HRP at
a dilution of 1:20000 1%BSA in PBST was added to the plate and allowed to incubate 1
hr at room temperature. The plate was washed again and R&D substrate detection reagent
(DY999) was added. The plate was allowed to incubate 5-10 min and the reaction was
stopped with 2N H2SO4. The plate absorbance was read at 450 nm and 570 nm. To
calculate the final O.D., the reading at 570 nm was subtracted from the reading at 450
nm, followed subtracting the reading for each sample on the BSA coated plate to account
for non-specific binding. A positive reading was considered any O.D. 3x that of a
secondary only control well.
TGF-β Activation
Conditioned media containing latent TGF- from Caco-2 cells was treated with
heat (100C for 10 min), 1N HCl, thrombospondin-1 (TSP-1; 4g/ml), or purified
HAstV-1 (10% by volume). Excluding the heat treatment, all samples were allowed to
incubate for 1 hr. Following incubation, the HCl was neutralized with 1N NaOH. Then
all samples were assayed for active TGF- using the PAI assay as previously described.
Neutralization Assay
HAstV-VA1 was pre-incubated with dilutions (1:50 and 1:100) of IVIG for 1 hr at
room temperature. Following incubation, Caco-2 cells were infected (MOI 1) with the
virus-antibody mixture. After a 1 hr adsorption period, the virus-antibody mixture was
removed and fresh media was replaced. At 5 days post-infection, RNA was extracted
from supernatants and cell lysates using Qiagen’s Viral RNA Extraction Kit. Quantitative
RT-PCR was performed according to the previously published protocol for HAstVVA1.68
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CHAPTER 4. ASTROVIRUS INDUCES REPLICATION-DEPENDENT
EPITHELIAL-MESENCHYMAL TRANSITION IN CACO-2 INTESTINAL
EPITHELIAL CELLS
Introduction
Human astroviruses (HAstV) are small, non-enveloped positive-sense singlestranded RNA viruses in the Astroviridae family. They are a leading cause of diarrhea in
children, the elderly, and immunocompromised people. Around 90% of the population
ages 9 years and older have detectable antibodies to HAstV-1.346 Despite its
prevalence,97,152,155 astrovirus remains under studied due to its perceived low clinical
impact and our knowledge surrounding astrovirus pathogenesis including the mechanism
used to cause diarrhea is limited.
Epithelial cells, the main cell type infected by HAstVs, line the intestinal lumen
and function as a barrier that absorbs nutrients and electrolytes while restricting entry of
harmful substances or pathogens.347 Breaches in this barrier by death of the epithelial
cells or disruption of cellular junctions through non-cytopathic mechanisms or
inflammation are associated with gastrointestinal diseases including irritable bowel
syndrome, Crohn’s disease, and colitis.348 We have demonstrated that astrovirus disrupts
the intestinal barrier through a novel mechanism independent of cellular damage or
induction of the host inflammatory response. 39,41 Instead, astroviruses increase barrier
permeability by dysregulation of cellular junctions.349 This disruption of barrier function
does not require productive infection; the viral capsid protein alone is sufficient to cause
disruption in vivo and in vitro. 349,350 Following gene set enrichment analysis of HAstV-1infected and uninfected Caco-2 cells, we observed that the hallmark pathway of
epithelial-mesenchymal transition (EMT) was significantly upregulated. We hypothesize
that the reorganization of junctional proteins was the first sign of a much bigger process
and that HAstV infected cells are undergoing EMT.
During EMT, polarized epithelial cells undergo changes to assume a more
invasive and mesenchymal phenotype. Part of this complex process is the reprogramming
of gene expression, regulated by numerous signaling pathways. Activation of these
signaling pathways ultimately results in the upregulation of EMT associated transcription
factors Snail1/2, Twist, and ZEB1/2351 among others. These transcription factors
negatively regulate epithelial markers such as occludin, claudins, and E-cadherin, while
positively regulating mesenchymal genes like N-cadherin, fibronectin, and vimentin.183
These changes at the genetic level allow for the hallmark phenotypic changes associated
with EMT like the disassembly of the epithelial cell-cell junctions, the loss of apicalbasal polarity, and the formation of lamellipodia or filopodia to enable migration and
invasion.175 One such regulator of EMT is transforming growth factor-beta (TGF-β).351–
353
When activated via phosphorylation by the TGF-β type 1 receptor kinases, SMADs
dimerize and translocate to the nucleus where they directly bind to DNA or transcription
factors, inducing or repressing EMT related genes.213,353 Previously we have shown TGFβ activity is increased during TAstV-2 infection in turkey poults.39
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Activation of signaling pathways initiating EMT can come from a number of
different extracellular cues including from pathogens. To date, only a handful of viruses
are known to induce EMT: hepatitis B virus (HBV),354 hepatitis C virus (HCV),355 human
papilloma virus (HPV),356 Epstein-Barr virus (EBV),357 and cytomegalovirus
(CMV).358,359 These viruses are oncogenic, and EMT is thought be a mechanism by
which they cause metastases, hepatocellular carcinoma, cervical carcinomas, and
lymphoma among other diseases. More recently, rhinovirus360,361 and transmitted
gastroenteritis coronavirus (TGEV),341 were shown to induce EMT yet the role in those
viral pathogeneses remains unknown. Here we characterize HAstV-induced EMT. This
process beginnings with the dysregulation of cellular junctions and an upregulation of
EMT related genes at 8 hours post-infection (hpi). In addition, we show disruption of cell
polarity and gain of vimentin by 24 hpi. While TGF- is activated during HAstV
infection, it does not appear to play a role in early EMT induction. To our knowledge,
these studies are amongst the first focused on understanding virally-regulated EMT that is
unassociated with oncogenesis.
Results
HAstV Infection Leads to Time-Dependent Reorganization and Decrease of
Junctional Protein Expression
To determine the extent of junctional disruption during HAstV infection, Caco-2
grown on glass coverslips were infected with HAstV-1 and stained for tight junction
proteins (occludin and ZO-1) and adherens junction proteins (E-cadherin and β-catenin)
at 6, 12, 18, and 24 hpi. While mock-infected cells showed normal cell junction
morphology, HAstV-infected cells have disrupted junctional proteins. This disruption
was seen as early as 6hpi with occludin beginning to re-localize away from the cell
periphery (Figure 4-1). Cellular junction disruption was followed by ZO-1 re-localizing
from the cell membrane at 18 hpi. The most striking finding was the reorganization of Ecadherin, a key marker of epithelial cells,362 from infected cells. E-cadherin is crucial in
the establishment and maintenance of the cellular junction complex as a whole,363,364 and
aberrant expression of E-cadherin is a hallmark of epithelial dysregulation.351 This
disassembly of epithelial cell-cell contacts, especially the disruption of E-cadherin,
during HAstV-1 infection suggested infected cells are undergoing EMT.
HAstV Infection Leads to EMT-Associated Gene Modulation
EMT is a transcriptionally regulated process. To establish HAstV-1 infected cells
were transitioning, we examined mRNA levels of EMT associated genes at 8, 24 and 48
hpi by multiplexed qRT-PCR using Qiagen’s RT2 Profiler system (Figure 4-2). A
number of EMT pathways associated with the induction of EMT were upregulated at
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Figure 4-1. HAstV-1 Infection Leads to a Time-Dependent Reorganization and
Decrease in Junctional Protein Levels.
Caco-2 monolayers on grown coverslips, infected with HAstV-1 (MOI 10) or mock
infected. Cells were fixed at 6, 18, and 24 hpi in 4% paraformaldehyde and then stained
for the indicated junctional proteins. Arrows indicate areas of junctional disruption.
Images are representative of at least 3 independent experiments.
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Figure 4-2. EMT-Associated Genes Modulated by HAstV Infection.
Heatmap showing fold regulation of EMT associated genes from Qiagen’s RT2 Profiler
PCR Array Human Epithelial to Mesenchymal Transition (EMT). RNA samples were
collected from HAstV-infected or mock-infected cells at 8, 24, and 48 hpi. Gene
expression values are colored corresponding to the up (red) or down regulation (blue).
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8hpi including, Wnt, TGF-, Notch, and Akt. We validated the RT2 Profiler findings by
measuring mRNA levels of E-cadherin (CDH1), occludin (OCLN), Snail (SNAI1), and
vimentin (VIM) by RT-PCR. The epithelial genes, CDH1 and OCLN, were
downregulated as early as 8 hpi (Figure 4-3A). The mesenchymal genes SNAI1 and VIM
were strongly upregulated by 18 and 24 hpi, respectively. Transcriptional changes were
reflected at the protein level, suggesting and that the junctional proteins were not simply
reorganized but were downregulated. Over the course of 24 hours, expression of the
junctional proteins occludin (p<0.0001), E-cadherin (p<0.0001), ZO-1 (p=0.0058), and βcatenin (p=0.0139) were all significantly decreased (Figure 4-3B, C). Additionally, we
observed an increase vimentin staining correlating to the increase in vimentin mRNA
(Figure 4-3D).
HAstV-Induced EMT Disrupts Cellular Polarity
Cellular junctions act as a physical barrier that prevent the movement of lipids
and membrane proteins from the apical cell membrane to the basolateral membrane and
vice versa.365 When cellular junctions are disassembled, proteins that were once localized
to the basolateral membrane freely migrate to the apical side causing a loss of cellular
polarity.366 To determine if cellular polarity was disrupted during HAstV-1 infection, we
stained for ezrin, a cytoplasmic linker between the apical membrane and the actin
cytoskeleton,367 and sodium-potassium ATPase (Na/K-ATPase), a transporter localized to
the basolateral membrane.368 In mock infected cells ezrin was distinctly localized to the
apical side and Na/K-ATPase to the basolateral with very little overlap (Figure 4-4A).
However, by 24 hpi there was less organized arrangement for both proteins and
significant co-localization. We noticed that cells appeared to lift or be extruded from the
cell monolayer (Figure 4-4A, bottom panel). To quantitate the disruption of polarity, we
measured the amount of Na/K-ATPase at the apical membrane. At 24 hpi, there was
significantly more Na/K-ATPase located at the apical membrane than in mock-infected
cells (Figure 4-4B, C).
TGF-β Activity Is Increased during HAstV Infection
We next asked what viral and/or cellular factors were involved in HAstV-induced
EMT. When examining the genes upregulated early in HAstV infection prior to the
induction of EMT, we observed that TGF- mRNA was increased at both 8 and 24 hpi.
Since TGF- is a classical activator of EMT, we asked whether this increase in message
translated to an increase in TGF- activity using a specific biological reporter assay
where mink lung (Mv1Lu) epithelial cells stably expressing the PAI-promoter upstream
of luciferase.344 Supernatants collected from HAstV-1 infected Caco-2 cells between 4
and 24 hpi were added to the Mv1Lu-PAI cells and TGF- activity was quantitated.
Supernatants from HAstV-1- infected cells contained significantly more active TGF-
compared to mock-infected cells beginning at 6 hpi and peaking at 12 hpi (Figure 4-5A).
Of interest, staining HAstV-1 infected Caco-2 cells for SMADs, the primary signal
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Figure 4-3. HAstV-1 Infection Leads to a Decrease in Epithelial Markers while
Increasing Mesenchymal Markers.
(A) Specific EMT genes of interest show epithelial genes (OCLN and CDH1) are down
regulated and mesenchymal genes (SNAI1 and VIM) are upregulated during the course of
HAstV-1 infection. Error bars indicate standard deviations, and asterisks show statistical
significance as measured by two-way ANOVA followed by Tukey’s multiple
comparisons test as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001. (B) Expression of
epithelial markers, occludin (Ocln), E-cadherin (E-cad), ZO-1, and β-catenin (β-cat),
were quantified by immunoblot of HAstV-1 or mock infected Caco-2 cell lysates. (C)
Bands were then quantified by densitometry and normalized to β-actin then compared to
mock-infection. Error bars indicate standard deviations, p-value as measured by ordinary
one-way ANOVA followed by a test for trend is indicated for each protein. (D) Caco-2
monolayers infected and fixed as previously described and stained for vimentin.
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Figure 4-4. HAstV-1 Infection Leads to a Disruption of Cellular Polarity.
(A) Caco-2 infected with HAstV-1 or mock infected (as indicated). Cells were fixed at 24
hpi in 100% ice-cold methanol and then stained for ezrin (red), sodium-potassium
ATPase (green), and DAPI (blue). (B) Basal or apical localization of sodium-potassium
ATPase was determined by measuring intensity above and below cell midline using
ImageJ. Error bars indicate standard deviations, and asterisks show statistical significance
as measured by the two-tailed student t test as follows: *, P < 0.05; **, P < 0.01; ***, P <
0.001.
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Figure 4-5. TGF-β Activity Increases during the Course of HAstV-1 Infection.
(A) Supernatants were collected from Caco-2 infected with HAstV-1 or mock infected
from 4 to 48 hpi. Supernatants were then assayed for active TGF-β using the PAI assay as
described previously.344 Error bars indicate standard deviations, and asterisks show
statistical significance as measured by two-way ANOVA followed by Sidak’s multiple
comparisons test as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001. (B) Caco-2 cells
mock infected, HAstV-1 infected, or treated with 20ng of TGF-β stained for SMAD3
(red), astrovirus capsid protein (green) and DAPI (blue).
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transducers for TGF- β,213 showed increased SMAD3 signal in uninfected bystander cells
(Figure 4-5B). This suggests that uninfected cells in the monolayer may be responsible
for the TGF- activation in response to HAstV infection.
Inhibition of TGF-β Activity Does Not Prevent HAstV-Induced EMT
TGF- is considered the hallmark inducer of EMT. Thus, we asked if HAstVinduced EMT was dependent on TGF-. To test, TGF- signaling was inhibited using the
small molecule inhibitor 370,369 which selectively inhibits the phosphorylation of the
TGF- type I receptor. Despite inhibiting TGF- activity, SB431542 had no impact on
HAstV-1-induced transcriptional regulation of genes associated with EMT
(Figure 4-6A), and failed to rescue E-cadherin protein expression (Figure 4-6B). Finally,
the addition of active TGF-β1 alone did not induce EMT with the same kinetics as
HAstV did. We did not see loss of E-cadherin or disruption of polarity until 3 days postinoculation with 20ng TGF-β (Figure 4-7). Overall, these studies suggest that activation
of TGF-β during infection is not the primary mechanism for HAstV-1-induced EMT.
However, we cannot discount the possibility that TGF- plays a critical role in EMT
induction in vivo or in low MOI infections.
HAstV-Induced EMT Is Replication Dependent
We previously demonstrated that HAstV-induced reorganization of occludin and
increased barrier permeability were independent of viral replication both in vitro349 and in
vivo.350 Thus, we asked if viral replication was necessary for EMT induction. To test, we
inoculated Caco-2 cells with UV-inactivated virus as previously described349 and
assessed EMT. With the UV-inactivated virus failed to reduce E-cadherin expression or
disruption of cellular polarity (Figure 4-8A, B). UV-activated virus also did not cause a
decrease in CDH1 or an increase in SNAI1 mRNA like observed with live virus
(Figure 4-8C). Further, inhibition of ERK1/2 with U0126, which we demonstrated
reduced HAstV replication,370 rescued some E-cadherin expression and cellular polarity
(Figure 4-8D, E).These studies suggest that productive replication is required for the
induction of EMT.
Discussion
We demonstrated the astroviruses increased barrier permeability by dysregulating
tight junction, specifically occludin.349 These studies expand upon that data to
demonstrate that HAstV induces epithelial cells to undergo EMT. This induction is
characterized through transcriptional changes leading to a downregulation of CDH1 and
OCLN early after infection followed by the upregulation of the key transcriptional factor
SNAI1. This decrease of the transcription of key epithelial cell-specific genes is
accompanied by the up regulation of mesenchymal cell-specific genes like VIM. These
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Figure 4-6. Inhibition of TGF-β Signaling with SB431542 Does Not Inhibit
HAstV-1-Induced EMT.
(A) RNA extracted at 24 hpi from Caco-2 cells infected with HAstV-1, TGF-β treated, or
mock infected with or without 10μM SB431542 shows SB431542 does not rescue
CDH1, SNAI1, or VIM regulation in HAstV-induced EMT. (B) Expression of epithelial
marker, E-cadherin, was quantified by immunoblot of HAstV-1 or mock infected Caco-2
cell lysates with or without 10μM SB431542. Bands were then quantified by
densitometry and normalized to β-actin then compared to mock-infection. All error bars
indicate standard deviations, and asterisks show statistical significance as measured by
ordinary one-way ANOVA followed by Dunnett’s multiple comparisons test as follows:
*, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 4-7. TGF-β-Induced EMT in Caco-2 Cells.
(A) Western blot of E-cadherin and vimentin at 1, 2, 3, and 4 days post inoculation with
20 ng active TGF-β compared to mock. (B) Caco-2 inoculated with 20ng active TGF-β or
mock treated (as indicated). Cells were fixed at 1, 2, or 3 days post-inoclation in 100%
ice-cold methanol and then stained for ezrin (green), sodium-potassium ATPase (red),
and DAPI (blue).
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Figure 4-8. Replication Is Required for HAstV-1-Induced EMT.
(A) Expression of epithelial marker, E-cadherin, was quantified by immunoblot of
HAstV-1, UV-inactivated HAstV-1, or mock infected Caco-2 cell lysates. Bands were
then quantified by densitometry and normalized to β-actin then compared to mockinfection. (B) RNA extracted at 24 hpi from Caco-2 cells infected with HAstV-1, UVinactivated HAstV-1, or mock infected show UV-inactivated virus does not modulate
CDH1 or SNAI1 regulation as active HAstV-1 does. (C) Sodium potassium ATPase
localization in Caco-2 cells infected with UV-inactivated HAstV-1 shows no difference
to mock infected cells. (D) Expression of E-cadherin was quantified by immunoblot of
HAstV-1, HAstV-1 in the presence of 10μM U0126, or mock infected Caco-2 cell
lysates. Bands were then quantified by densitometry and normalized to β-actin then
compared to mock-infection. (E) Sodium potassium ATPase localization in Caco-2 cells
infected with HAstV-1 in the presence of 10μM U0126 and mock infected cells. All error
bars indicate standard deviations, and asterisks show statistical significance as measured
by ordinary one-way ANOVA followed by Dunnett’s multiple comparisons test as
follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001.

47

48

transcriptional changes result in decreased epithelial protein levels leading to a
breakdown of the cell junctions resulting from the loss of those proteins from the cell
periphery. Accompanying this is a subsequent loss of cellular polarity by 24 hpi. Despite
an increase in active TGF- during HAstV infection, inhibition of TGF- signaling did
not prevent the EMT phenotype; HAstV-induced EMT is replication dependent. EMT is
a rare phenomenon triggered by only a few viruses and even less non-oncogenic viruses,
making HAstV-induced EMT a truly unique finding.
The observation that HAstV induces EMT during infection generates more
questions that will need to be resolved before we will fully understand its role in HAstV
pathogenesis. The first question raised by our findings concerns the benefit of inducing
EMT during infection. For the oncogenic viruses that induce EMT it’s simple; this
process promotes metastasis, enabling these viruses to spread throughout the host, clearly
benefiting the virus. However, for the non-oncogenic viruses it’s not as clear.
Researchers studying EMT in rhinovirus and TGEV infection propose similar rationale as
to why their virus of interest induces EMT. Faris et al. suggest rhinovirus infection alters
the structure and function of airway epithelium and increases the susceptibility to
secondary infection. By facilitating secondary infection, rhinovirus can alter the cytokine
and chemokine responses.361 Xia et al. also suggest TGEV induces EMT to promote
colonization of ETEC in the intestinal epithelium.341 Alone TGEV provokes a robust
cytokine response, however upon co-infection cytokine levels were decreased, possibly
assisting to decrease clearance of both pathogens.371,372 At first glance, it would appear
that inducing EMT would be beneficial for HAstV. This process produces gaps in the
intestinal barrier that the virus can exploit and gain access to the rest of the body. We
have seen in the turkey model and now in cases of HAstV infection that astrovirus has the
potential for systemic spread. However, there could be an argument for this process to
benefit the host. In our polarity staining, we noticed cells that appeared to be extruded out
of the cell monolayer (Figure 4-4A). We questioned if the host was inducing EMT in a
wound healing response, where infected epithelial cells are extruded and mesenchymal
cells fill in the gaps in the monolayer. This could prevent extensive damage and
inflammation for the host which is a unique factor already seen in astrovirus
infections.39,40
The extrusion of infected cells could still prove to be a benefit to the virus, since
infected cells would be released into the intestinal lumen, shed in feces and allow for
spread to new hosts. This raises another questioning the link between EMT and
symptoms of astrovirus infection. Previous research has attempted to link the barrier
permeability seen during infection with the main symptom of astrovirus, diarrhea. Recent
reports now show an association with astrovirus infection and severe extragastrointestinal symptoms,152 such as encephalitis and meningitis. We know that HAstV
is able to disrupt barrier integrity via EMT, but it is unknown whether this is specific to
intestinal barriers or if could extend to others such as the blood brain barrier.
Investigations into the association of symptoms and EMT are currently ongoing.
Determining if EMT plays a role in the dissemination of astrovirus from the
gastrointestinal tract to the central nervous system could even provide new therapeutic
targets for systemic HAstV infection.
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Previously we have shown that barrier permeability and disruption of some
junctional proteins such as occludin is replication independent.349 Yet, here we show that
replication is required for the induction of EMT. We hypothesize that there may be a
binding event that is sufficient to cause some barrier permeability and the re-localization
of occludin thus allowing the capsid protein alone to cause these events. However, a more
intricate signaling cascade is triggered during replication of the virus that induces the
EMT phenotype. Further research is needed to determine the exact aspect of replication
that is triggering EMT, such as the processing of a non-coding part of the genome or the
production of a non-structural protein.
Although the cleavage process of the HAstV nonstructural polyproteins is still not
well characterized, it has been suggested at least four nonstructural proteins in addition to
an RNA-dependent RNA polymerase (RdRp) are produced during replication.373
However, the exact function of these nonstructural proteins remains undetermined. It has
been shown that genetic variation in at least one of the HAstV nonstructural proteins can
impact viral RNA production and the amount of infectious virus shed.374,375 Studies of the
oncogenic viruses that induce EMT have shown strong evidence that viral proteins are
heavily involved. The X protein of HBV,354,376–378 NS4B379 and core protein of HCV,380–
382
E5383 and E6/E7 oncoproteins of HPV,384,385 nuclear antigens386 and latent membrane
proteins of EBV,387–389 and immediate early proteins 1 and 2 of CMV358 have all been
shown to induce EMT. While viral proteins have not been reported to play a role in EMT
for rhinovirus or TGEV, studies on EMT with these two viruses are limited and therefore
should not be ruled out. Given this, it could be possible one of the nonstructural proteins
or a cleavage product may impact the induction of EMT during HAstV infection. While
we currently lack the tools necessary for additional studies focused on the nonstructural
proteins, we are in the process of developing them. These studies will be critical in order
to definitively identify the viral factors involved in HAstV-induced EMT.
During replication, there is also may be the processing of microRNAs (miRNA).
Recently there have been many reports in the literature of non-coding miRNAs regulating
EMT.270,271 Many have been shown to inhibit EMT, like the miR-220 family members
(miR-200a, miR-200b, miR-200c, miR-141, and miR-429) that directly repress
ZEB1/2.273–276 In addition, miR-30a inhibits EMT non-small cell lung cancer by directly
targeting Snail.277 However, not all miRNAs inhibit EMT, overexpression of miR-10b
initiates metastasis by inhibiting translation of HOXD10, resulting in increased
expression of RhoC.390 Furthermore, miR-373 and miR-520c stimulate tumor invasion by
down-regulating CD44.284 At this time, there are more than seventy different miRNAs
reported to be involved in EMT regulation.269 It is known that many viruses encode their
own miRNAs,391 and in the case of EBV these miRNAs have been reported to facilitate
EMT.392,393 Ongoing studies in our lab is looking at cellular miRNAs modulated during
HAstV infection as well as identifying miRNAs encoded within the astrovirus genome.
Since we know HAstV-induced EMT is replication dependent, it would make sense that
something during replication like the processing of a miRNA could be inducing EMT.
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While TGF-β is induced during HAstV replication, here we show the TGF-β
inhibitor, SB431524 did not inhibit HAstV-induced EMT. SB431542 acts by inhibiting
the phosphorylation of the type I TGF- receptor, and preventing the activation of
SMADs.369 However, TGF- can activate EMT through SMAD independent pathways,
that would not be affected by SB431542.369 For example, TGF- can induce the
activation of the PI3K/Akt pathway independent of SMADs. This pathway has also been
previously reported to be active during HAstV infection.394 However, if this pathway was
responsible for induction of EMT in our system, we would expect to see a either an
upregulation of Twist or a down regulation of GSK-3,395 neither of which is indicated
by our data (Figure 4-2). PI3K/Akt can also crosstalk with Wnt/-catenin signaling.
However, this signaling would result in β-catenin accumulating in the nucleus, which is
not seen in Figure 4-1. Although our data suggests that TGF- is likely not the main
mechanism utilized by HAstV to induce EMT, we believe it is still an important factor in
astrovirus pathogenesis. TGF- is upregulated in activity both in vitro and in vivo,39 so it
must be an integral part of the viral replication cycle. Interestingly, our SMAD staining
showed that TGF- signaling is mostly occurring in non-infected cells in the epithelial
monolayer. This bystander effect is likely very important in vivo where TGF- can create
an immune suppressive microenvironment396 and could account for the lack of
inflammation see in in vivo astrovirus infections. Future studies will look at the role of
TGF- activation in astrovirus replication.
In conclusion, we demonstrated HAstV induces EMT in a replication dependent
manner. This finding not only leads us one step closer in understanding astrovirus
pathogenesis but also in understanding EMT from the perspective of a non-oncogenic
virus. EMT leads to dysfunction of the epithelial barrier. In vivo, barrier dysfunction in
the gastrointestinal system results in gaps in the epithelium that pathogens can take
advantage of to spread throughout the body. Previous research has already shown the
capability of astrovirus to spread systemically in turkey poults. Recent reports are now
showing more cases of systemic HAstV infection, even causing severe CNS symptoms
like encephalitis and meningitis. During systemic infections, the immune system becomes
overwhelmed and cannot clear the virus alone. In addition, the majority of severe HAstV
infections occur in individuals that already have compromised immune systems.
Currently, there are no antiviral treatment options for HAstV infection. When these cases
arise, clinicians and physicians do not have proven treatments to offer patients. In the
next chapter, we sought to determine if any known antivirals were effective in treating
astrovirus infection.
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CHAPTER 5. ASTROVIRUS REPLICATION IS INHIBITED BY
NITAZOXANIDE IN VITRO AND IN VIVO2
Introduction
Diarrheal disease is the second leading cause of death in children under 5 years of
age, with nearly 1.7 billion cases and 525,000 deaths each year.397 Since their discovery
in 1975, human astroviruses (HAstV), which are positive single-stranded RNA viruses,
have consistently ranked among the leading causes of diarrhea worldwide.127 However,
human astrovirus infections can range from asymptomatic to mild diarrhea or rare
instances of fatal systemic disease.76,84 Infections in immunocompetent individuals
typically present as watery diarrhea that resolves within 1 to 3 days post-infection without
the need for hospitalization.127 Astrovirus outbreaks occur frequently in assisted living
facilities, hospitals, and child care centers, where the young, elderly, and
immunocompromised populations are at risk of persistent diarrhea, leading to wasting,155
and extragastrointestinal disease that may require medical intervention, including
respiratory disease,398–401 fatal encephalitis, and meningitis.87
Despite its high prevalence and the risk of severe disease, no vaccines or drug
treatments exist for astrovirus. Only oral or parenteral fluids and electrolytes are available
to prevent and treat dehydration caused by astrovirus-induced diarrhea. In these studies,
we provide the first evidence that nitazoxanide (NTZ), an FDA-approved broad-spectrum
antiparasitic and antiviral drug, inhibits the replication of multiple strains of human
astrovirus in vitro even when administered up to 8 h post-infection and reduces viral
shedding and diarrhea in vivo. This work highlights the potential use of NTZ as an
effective therapeutic strategy against astrovirus infection.
Results
Nitazoxanide (NTZ) Blocks Astrovirus Replication In Vitro
To identify an effective antiviral drug against astrovirus, human colon carcinoma
(Caco-2) cells were infected with a laboratory strain of human astrovirus strain 1
(HAstV-1) at a multiplicity of infection (MOI) of 1 before increasing concentrations of
antiviral compounds or dimethyl sulfoxide (DMSO; vehicle control) were added 1 h postinfection (hpi). The panel of antiviral compounds used in our study, foscarnet, ribavirin,
acyclovir, and nitazoxanide, were chosen upon the recommendation of clinical
colleagues, with acyclovir serving as a negative control. Viral capsid protein levels were
quantitated at 24 hpi by immunofluorescence microscopy as described previously.343
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Foscarnet, ribavirin, and acyclovir failed to inhibit HAstV-1 replication even at
concentrations of 250 μM (Figure 5-1A). In contrast, NTZ inhibited HAstV-1 replication
in a dose-dependent manner, with the 5 μM treatment completely blocking virus
replication (Figure 5-1A, B). The 50% effective concentration (EC50) was calculated as
approximately 1.47 μM (Figure 5-1C). Concentrations of NTZ above 5 μM were
associated with decreased cell viability compared to the cell viability with vehicle alone
(DMSO) (Figure 5-2). Thus, subsequent studies were performed with NTZ at a
concentration of 2.5 μM.
NTZ Inhibits dsRNA Production
To determine the stage of the viral replication cycle blocked by NTZ, drug was
added at 2, 4, 6, 8, and 12 h after HAstV-1 infection and viral capsid expression
quantitated (Figure 5-3A). The addition of NTZ up to 8 hpi completely inhibited HAstV1 replication (Figure 5-3B, D), suggesting it blocks a stage of the viral life cycle
following entry and uncoating but before structural protein production. Indeed, NTZ
reduced the formation of double-stranded RNA (dsRNA) that occurs when the astrovirus
genome is generated via its RNA-dependent RNA polymerase (Figure 5-3C, E). This
method serves as a proxy for replication, given our lack of antibodies to the HAstV-1
nonstructural proteins.
Previous work demonstrated that thiazolide, the active form of NTZ, upregulates
type I and II interferon (IFN) genes, which were critical for reducing HIV replication in
human peripheral blood mononuclear cells (PBMCs),402 Type I IFN limits HAstV
replication.58 Thus, to determine whether NTZ increased type I or III IFN within the time
frame it inhibits HAstV replication, we treated Caco-2 cells with NTZ or DMSO
(untreated) and quantitated interferon alpha (IFN-α), IFN-β, or IFN-λ mRNA levels at 2
and 4 h. At 4 h post-NTZ treatment, the shortest duration of time NTZ can be added and
still inhibit HAstV dsRNA production, IFN-α, IFN-β, and IFN-λ mRNA transcripts were
not significantly upregulated compared to their levels in DMSO-treated cells
(Figure 5-4), suggesting that NTZ inhibits HAstV independent of IFN induction. Future
studies will explore the mechanism of action.
NTZ Is Effective Across HAstV Serotypes
We next asked if NTZ was effective against multiple classical HAstV serotypes
and clinical isolates. Briefly, Caco-2 cells were infected with four different laboratoryadapted HAstV serotypes (HAstV-1, -2, -6, and -8) and four clinical isolates obtained
from patient samples (SJ177.110 [HAstV-2], SJ60.212 [HAstV-8], SJ88123.E120
[HAstV-1], and SJ88027.E259 [HAstV-1]) and treated with 2.5 μM NTZ or DMSO
(vehicle control). NTZ completely inhibited all HAstV isolates, suggesting it is broadly
protective against multiple HAstV serotypes (Figure 5-5).
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Figure 5-1. Nitazoxanide (NTZ) Inhibits HAstV-1 Replication in Caco-2 Cells.
(A) Caco-2 cells were infected with HAstV-1 at an MOI of 1 and treated with a panel of
antivirals (foscarnet, ribavirin, acyclovir, and nitazoxanide) at the indicated
concentrations. At 24 hpi, cells were fixed and stained with DAPI (blue) and for the
presence of astrovirus capsid protein (green). (B) The percentages of infected cells were
calculated and compared to the results for nontreated cells. (C) Nonlinear regression
analysis of percent infection data was used to determine the 50% effective concentration
(EC50). All error bars indicate standard errors of the means, and asterisks show statistical
significance as measured by ordinary one-way ANOVA as follows: *, P 0.05; **, P 0.01;
***, P 0.001.

54

Figure 5-2. Cytotoxicity of NTZ in Caco-2 Cells.
Cell viability of Caco-2 cells following 24 h of treatment with NTZ or vehicle alone
(DMSO) at the indicated concentrations was determined by MTT assay. All error bars
indicate standard errors of the means, and asterisks show statistical significance as
measured by multiple t tests as follows: *, P 0.05; **, P 0.01; ***, P 0.001.
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Figure 5-3. Nitazoxanide Inhibits HAstV-1 Replication In Vitro When Added Up
to 8 hpi.
(A) Caco-2 cells were infected with HAstV-1, and at the indicated times post-infection,
2.5M NTZ or vehicle alone (DMSO) was added. (B) At 24 hpi, cells were fixed and
stained with DAPI (blue) and for the presence of astrovirus capsid protein (green). (C) At
10 hpi, cells were fixed and stained with DAPI (blue) and for the presence of dsRNA
(green). (D) Quantification of the percentages of cells with capsid staining from the
experiment whose results are shown in panel B. (E) Quantification of the percentages of
cells with dsRNA staining from the experiment whose results are shown in panel C. All
error bars indicate standard errors of the means, and asterisks show statistical significance
as measured by multiple t tests as follows: *, P 0.05; **, P 0.01; ***, P 0.001.
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Figure 5-4. NTZ Does Not Induce Significant IFN Levels in Caco-2 Cells.
Real-time RT-PCR for IFN-α, IFN-β, and IFN-λ was performed on RNA collected from
Caco-2 cells treated with 2.5M NTZ and normalized to the value for GAPDH. Results are
shown as fold increases over the results for untreated cells, and error bars indicate
standard errors of the means.
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Figure 5-5. Nitazoxanide Inhibits the Replication of Multiple Serotypes and
Clinical Isolates of Human Astrovirus.
Caco-2 cells were infected with laboratory-adapted virus serotypes (top) or clinical
isolates (bottom) and treated with 2.5 M NTZ or vehicle alone (DMSO). At 24 hpi, cells
were fixed and stained with DAPI (blue) and for the presence of astrovirus capsid protein
(green).
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NTZ Reduces Viral Replication and Clinical Disease In Vivo
To determine if NTZ reduced disease in vivo, we used the only small animal
model exhibiting astrovirus-induced diarrheal disease, turkey poults.39 Briefly, 5-day-old
turkey poults were orally gavaged with 100 mg/kg of body weight NTZ once daily for
4 days prior to oral infection with intestinal filtrate containing between 1012 and 1013
genome copy units of turkey astrovirus strain 2 (TAstV-2) in 500 μl phosphate-buffered
saline (PBS) and then for 3 days post-infection (Figure 5-6A). The dose of NTZ used to
treat the turkey poults was selected based on previously published studies of NTZ
treatment in mice.403–405 Stool samples were scored daily by four blinded volunteers as
previously described.42 The scoring scale ranged from 1 to 4 based on color and
consistency, with scores of 3 and 4 being considered diarrhea. Stool samples were also
collected to quantitate viral titers. Although the difference was not statistically
significant, NTZ treatment resulted in fewer poults with clinical disease (Figure 5-6B).
This likely results from the significant reduction (P = 0.005) in stool viral loads
throughout the course of infection (Figure 5-6C). The poults also showed no adverse
symptoms from receiving NTZ alone. Excitingly, this gives evidence NTZ may be an
effective therapeutic for astrovirus-induced diarrheal disease.
Discussion
Our study provides the first evidence of an effective antiviral for astrovirus
infection. We showed that NTZ is broadly protective against multiple classical HAstV
serotypes and reduces the production of dsRNA during infection in vitro with an EC50 of
approximately 1.47 μM. Additionally, we showed the potential NTZ has as a clinical
therapeutic by its ability to reduce viral shedding and clinical disease in our symptomatic
turkey poult model.
Nitazoxanide [2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide] (Alinia; Romark
Laboratories) is a thiazolide compound for treatment of both intestinal protozoal and
helminthic infections, specifically Giardia lamblia and Cryptosporidium parvum.406
Recently, this compound has been shown to have antiviral properties as well. The use of
NTZ in vitro has been reported as an antiviral against influenza virus,407 rotavirus,408
norovirus,409 Japanese encephalitis virus (JEV),404 rubella virus,410 Zika virus,411 hepatitis
C virus,412 and hepatitis B virus.413 Successful clinical trials have demonstrated its
effectiveness in treating influenza virus,414 norovirus and rotavirus,409,415,416 hepatitis B
virus,417 and hepatitis C virus.412,418 Its mechanism of action against protozoa is due to its
interference with pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron
transfer reactions.419 While its antiviral action is currently unknown, research suggests it
may be through the induction of the interferon response via activation of protein kinase R
or disruption of the unfolded protein response.407 We show that NTZ disrupts astrovirus
infection early in the replication cycle, causing a significant decrease in the production of
dsRNA. The inhibition by NTZ at an early stage of infection was also seen with JEV.404
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Figure 5-6. Nitazoxanide Reduces Clinical Symptoms and Viral Titers in Turkey
Poults.
Turkey poults (n=6 per group) were infected with turkey astrovirus (TAstV-2) from
intestinal filtrate. For 4 days prior to infection and 3 days post-infection, poults were
treated with NTZ. Poults were monitored for clinical score daily, and stool samples were
collected to measure viral RNA titers every other day. (A) Percentages of poults with
clinical scores of 3 or higher in the treatment groups indicated in the key. PBS, no
antiviral treatment. (B) Viral RNA titers of stool samples collected from infected poults
with or without NTZ treatment. All error bars indicate standard errors of the means, and
dashed line represents the limit of detection. Asterisks show statistical significance as
measured by two-way ANOVA as follows: * , P 0.05; ** , P 0.01; *** , P 0.001.
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Recent research has shown that thiazolides upregulate type I and II IFN,402 which
modulate the immune system, and this could be how NTZ creates a broadly antiviral
state. However, the rapid kinetics with which NTZ inhibits HAstV replication
(Figure 5-3) suggests that the induction of IFN is not responsible. Studies to uncover the
exact mechanism will be difficult until further tools are available to investigate astrovirus
replication.
Human astroviruses are classified into genotypes, and within the classical human
genotype, comprising the genus Mamastrovirus 1 (MAstV1), strains are further divided
into serotypes (HAstV-1 to -8) based on their antigenicities and genetic differences in the
complete capsid sequences.127 These genetic differences between astrovirus serotypes can
confer differences in replication kinetics and symptom severity.420 Thus, finding a
compound that broadly inhibits astroviruses across genotypes and serotypes is crucial.
We found that NTZ is broadly protective across multiple HAstV serotypes, including the
dominant strain worldwide, HAstV-1.152 Future studies will assess the ability of NTZ to
inhibit the replication of the nonclassical HAstV genotypes, MLB and VA (MAstV6, -8,
and -9), which have been associated with rare cases of encephalitis or meningitis in
immunocompromised patients,87 although there has been 1 case of classical HAstVassociated encephalitis.
To evaluate efficacy in vivo, we turned to the turkey poult model. Turkey poults
exhibit age-dependent diarrhea similar to that in humans when infected with TAstV,
making them the only clinically relevant small animal model for astrovirus identified to
date.39,119 We found a significant decrease (P = 0.005) in stool viral titers, with NTZtreated poults having nearly 2 log less virus at 5 days post-infection. We also showed that
viral titers began to plateau in the NTZ-treated poults at 5 days post-infection, while
untreated poults still showed increasing titers. This suggests NTZ treatment may lead to
faster clearance of the virus. The decreased viral titers were associated with fewer poults
having clinical disease. It is not surprising that NTZ did not completely prevent clinical
disease. Viral titers are reduced but not completely inhibited. Furthermore, we
demonstrated that administration of viral capsid alone is sufficient to induce diarrhea in
turkey poults.42 Therefore, NTZ treatment may not be able to fully inhibit AstV-induced
diarrhea. Finally, we administered between 1012 and 1013 genome copy units to each
poult. While there have been reports of virus shedding in humans at this level,420 it is a
large viral dose that may not be representative of natural infection. Overall, this work
provides the first evidence that NTZ may be an effective antiviral option against human
classical HAstV and turkey astrovirus infections.
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CHAPTER 6.

CONCLUSIONS AND FUTURE DIRECTIONS

Previous research has shown that astrovirus pathogenesis is unique in that it
disrupts tight junctions to compromise barrier integrity.349 The studies in this dissertation
extend our initial work to demonstrate that this disruption of cellular junctions is just the
beginning; we show that astrovirus infection induces epithelial-mesenchymal transition
(EMT). Beginning with the loss of cell-cell contacts and a transcriptional upregulation of
EMT related genes at 8 hours post-infection (hpi), astrovirus infected cells display
disrupted cell polarity and express mesenchymal proteins like vimentin by 24 hpi. While
the exact mechanism by which HAstV induces EMT has yet to be determined, we have
shown this process is dependent on productive viral replication. In addition, these studies
have identified an FDA-approved antiviral that effectively inhibits astrovirus replication.
Nitazoxanide blocks astrovirus replication in vitro with an EC50 of approximately
1.47 μM and is effective against a broad range of human astrovirus serotypes. Through
the course of performing these studies, more interesting findings were revealed that will
require further investigation.
Soon after identifying the phenotypic changes associated with EMT, we sought to
determine the mechanism(s). We performed a microarray and gene set enrichment
analysis, between HAstV-infected and uninfected Caco-2 cells to examine which genes
were modulated by infection. The results from this microarray showed several cytokine
pathways were upregulated, including TNF- and TGF- related signaling. We initially
hypothesized that astrovirus-binding and/or replication, resulted in the secretion of a
cellular factor that induced EMT. Pro-inflammatory cytokines like TNF- and IL-6 are
known inducers of EMT.421–423 Despite previous work in the lab demonstrating a lack of
cytokine or chemokine production in the first 24 hours of infection, supernatants from
HAstV infected cells were collected at 18, 24, and 48 hpi. These supernatants were UVinactivated and placed on naïve Caco-2 cells to determine if a secreted factor was causing
increased barrier permeability and induction of EMT. None of the collected supernatants
caused a drop in TER (Figure A-1A). Supernatants from HAstV and mock infected cells
were then tested for the pro-inflammatory cytokine, TNF-, by ELISA because it was a
top upregulated hit in our microarray analysis. While, neither the supernatants from
HAstV or mock infected cells had significant levels of TNF-, the viral stocks did
contain trace levels of TNF- (Figure A-1B). This discrepancy is likely due to
experimental conditions. Viral stocks are prepared by infecting post-confluent Caco-2
cells in the presence of 10g/ml porcine trypsin, allowing for multiple round of infection,
and collecting the supernatant 4 days later. This contrasts to our experimental studies
which are conducted between 8 and 48 hpi without trypsin allowing for only a single
round of viral replication. This suggests that at least TNF- and potentially other cellular
factors may be released during multi-cycle replication and could be present in our viral
stocks. Thus, the viral stock was purified, shown to be free of TNF- and EMT assays
were performed. Purified viral stocks, free of detectable TNF- still induced EMT
(Figure A-1C), suggesting neither TNF-, some other secreted cytokine, nor possible
stock contaminants were responsible for HAstV-induced EMT.
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Another signaling pathway shown to be upregulated by our microarray analysis
was TGF-β. However, an increase in TGF- mRNA does not always equate to increased
TGF-β activity. When TGF-β is produced, it is in conjunction with a latency-associated
protein (LAP) that prevents TGF- from binding to its receptor. The LAP must be
removed in order to activate TGF-. Using the PAI biological assay, we observed an
increase in active TGF- during HAstV infection (Figure 4-5A). Latent TGF- can be
activated by a number of mechanisms including proteases, reactive oxygen, heat, acidic
pH, engagement with integrins and thrombospondin-1 (TSP-1).424 To determine what was
activating TGF-, conditioned media containing latent TGF- from Caco-2 cells was
incubated with purified HAstV as well as known activators of TGF- (heat, 1N HCl, and
TSP-1). We discovered that purified HAstV can directly activate latent. While HAstV is
not as potent of an activator as heat or HCl, it did activate TGF- above background
levels (Figure B-1). Although collectively our data indicates that TGF- is likely not the
main mechanism utilized by HAstV to induce EMT, these results suggest is still an
important factor in astrovirus pathogenesis. TGF- is likely very important in vivo in
creating an immune suppressive microenvironment. Additionally, it may be important in
inducing EMT in bystander cells at later times post-infection. Future studies will examine
how HAstV is directly activating TGF- and how TGF- affects astrovirus replication.
Since our data suggested TGF- was not the main mechanism inducing EMT, we
investigated other less common inducers of EMT like miRNAs. Our lab showed several
cellular miRNAs were modulated during HAstV infection, but none of these were
involved in the increased barrier permeability during infection. We then identified three
miRNAs encoded in the HAstV genome. MiR-487a, a miRNA encoded into the capsid
portion of the HAstV genome, impacted HAstV-induced barrier permeability as well as
viral replication. Interestingly, miR-487a has been reported to be involved in TGF-mediated EMT.425 We wanted to determine whether miR-487a played a role in HAstVinduced EMT. We screened clinical isolates, our lab has collected through longitudinal
cohort studies of the St. Jude patient, for sequence homology to miR-487a and three
isolates with varying degrees of similarity to miR-487a were identified. Caco-2 cells
were infected with these three isolates and the characteristics of HAstV-induced EMT
were examined. One isolate in particular, CI-110, that had very little sequence homology
to miR-487a, exhibited delayed barrier permeability kinetics, and higher expression of Ecadherin than the other isolates and the lab adapted HAstV-1 (Figure C-1). This finding
was extremely intriguing, as other viruses have been shown to use miRNAs to induce
EMT.391–393 However, more investigations are needed to validate this finding.
Following the examination of the mechanism of HAstV-induced EMT, we asked
what the role of EMT is in the context of astrovirus pathogenesis. Both my studies and
those previously published349 showed that occludin was the first junctional protein to be
disrupted during HAstV infection (Figure 4-1). Using cells with occludin knocked down
by 75% via shRNA (a generous gift from Dr. Carolyn Coyne) (Figure D-1A), we sought
to determine if the disruption of occludin was necessary for HAstV replication and EMT.
When occludin levels are reduced, the percent of HAstV infected cells in the monolayer
increases (Figure D-1B, C). I hypothesize that in the absence of occludin, the receptor
used by HAstV may be more accessible and allow a greater percentage of cells to be
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infected. Despite the difference in infection between the knockdown cells and Caco-2,
there was no difference in the amount of virus released into the supernatant suggesting a
possible role for occludin in viral egress. Studies have shown that occludin reorganization
is mediated by phosphorylation.426–428 I hypothesize the ERK signaling cascade, which
our lab has showed was activated within 30 minutes of HAstV infection,370 and which
was necessary for HAstV-induced EMT (Figure 4-8), could mediate phosphorylation of
occludin and its subsequent reorganization. Future work will solidify the role of occludin
in astrovirus pathogenesis and EMT.
EMT may also contribute to pathogenesis by permitting astrovirus to cross the
intestinal epithelium and cause systemic infection. EMT disrupts barrier integrity and
creates gaps that pathogens can use to gain access to the body. Disseminated astrovirus
infections have been reported in animals for decades. More recently novel HAstV
genotypes were reported to be associated with cases of encephalitis and meningitis. In the
past year, two St. Jude patients required treatment for HAstV-VA1-induced encephalitis.
Since there have been only a few reported cases of HAstV-VA1 infection and even fewer
with positive outcomes (60% fatality rate; Table 1-1), physicians had very little
information on effective treatments. Based on our antiviral work, our clinical colleagues
administered NTZ to both patients. Both survived their infections. HAstV encephalitic
patients have also been administered intravenous IgG (IVIG), as this has been proposed
as a treatment option for HAstV. We questioned whether commercially available IVIG
had HAstV-VA1 specific antibodies and if it could confer neutralization of the virus, to
determine if the treatment should be continued. ELISA assay demonstrated nine different
lots of IVIG all had equal amount of HAstV-VA1 specific antibodies. Surprisingly, there
were significantly more HAstV-VA1 antibodies than HAstV-1 (Figure E-1A, B). Studies
of HAstV prevalence have always suggested that HAstV-1 is the most common HAstV
infection.152,155 These results and more recent studies would suggest that HAstV-VA1
may be just as prevalent, or that antibodies to HAstV-VA1 are more long-lasting. When
examining the neutralization of these antibodies, one lot showed some neutralization
capacity at a dilution of 1:50 (Figure E-1C, D). It appears that these antibodies may be
able to block entry, since there was a reduction in cell bound genome copies but not in
the supernatant. Given these results, IVIG may serve as another treatment option for
severe HAstV infection. However, due to the cost of IVIG treatments, it may not be
feasible in all cases. Although we have not shown NTZ inhibits novel HAstV genotypes,
I hypothesize it would inhibit these genotypes as well, because NTZ blocked the
formation of dsRNA, a necessity among all astroviruses. We now have HAstV-VA1
propagated in the lab and will investigate this novel genotype in the future.
While EMT is clearly embedded as part of astrovirus pathogenesis, we do need to
question why this process is happening and whether it is a benefit to the virus, the host, or
both. As discussed in Chapter 4, EMT is induced by a handful of viruses, the majority of
which are oncogenic. With these viruses, EMT is a means to create secondary metastases
and spread to new areas of the body. However, in the case of the non-oncogenic viruses
the need of EMT is less obvious. It has been suggested for both TGEV and rhinovirus
that the induction of EMT and the associated increase in TGF- create an
immunosuppressive microenvironment.340,341 This could be the case for HAstV since a
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lack of inflammation is a hallmark of astrovirus infection. Additionally, we observed
cells that appeared to be extruded out of the cell monolayer during astrovirus infection
(Figure 4-4A). This made us question if HAstV-induced EMT was part of the wound
healing process. This would make sense as EMT is heavy involved in wound repair and if
HAstV-induced EMT were to be categorized into one of the three types of EMT
discussed in Chapter 2, it most closely resembles type II EMT. Whether EMT benefits
HAstV or the host is still a difficult question to answer with the data my studies have
generated. On the one hand, creating an immunosuppressive microenvironment probably
benefits the virus more than host. On the other hand, closing gaps in the intestinal
epithelium is more of a necessity for the host. Throughout these studies, very high MOI
was used during infections to get as many cells in the monolayer infected as possible.
While RNA was extracted from the entire monolayer, there was never 100% infection.
This leaves the possibility of non-infected bystander cells responding to neighboring cells
infected with HAstV. We saw glimpses of this in staining for SMAD3 (Figure 4-5),
where SMAD3 translocated to the nucleus mainly in non-infected bystander cells. By
using either cell sorting of infected cells or through single-cell transcriptomics, it would
be possible to determine if transcriptional regulation of EMT was occurring in infected
cells, non-infected cells, or both. I would then hypothesize if EMT is occurring in
infected cells, the process is a benefit to the virus; if it is occurring in bystander cells, the
process is a result of the virus but a benefit to the host.
In addition to performing cell sorting or single cell transcriptomics, further
investigation into miR-487a as a possible mechanism for HAstV-induced EMT needs to
be conducted. First, we need to show miR-487a is expressed during infection. Sequence
homology to this miRNA was identified, but that does not mean it is actually expressed
and processed in our system. Additionally, the clinical isolates used were different
serotypes of HAstV, meaning there are other genetic differences in these viruses aside
from their sequence homology to miR-487a. Ideally, to determine if miR-487a is
involved in HAstV-induced EMT, we would use site directed mutagenesis to alter the
miRNA sequence without modifying the remainder of the capsid genome or structure.
Finally, we would need to identify the target of miR-487a whose down-regulation would
be responsible for inducing EMT. These measures will allow us to determine the role of
miR-487a in HAstV-induced EMT. Another clinically relevant aspect of this study that
needs further investigation is whether the novel genotypes induce EMT. These genotypes
are at the root of the most devastating HAstV disease whose prevalence is much more
common than once thought and yet so little is known about them. By determining if these
genotypes induce EMT, we can gain a little more insight into what separates them from
other HAstV, while possibly generating more therapeutic targets to treat systemic
infection.
In conclusion, the studies performed in this dissertation have provided
fundamental new research on astrovirus pathogenesis as well as new treatment options. In
addition, the work and outcomes outlined above provide a platform for further research to
build upon and create new areas of astrovirus research. The finding that a non-oncogenic,
enteric virus such as HAstV induces EMT will hopefully lead to new investigations of
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non-oncogenic viruses and novel areas of research into the pathophysiology of the
gastrointestinal tract by viruses.
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APPENDIX A. PRO-INFLAMMATORY CYTOKINES ARE NOT
RESPONSIBLE FOR HASTV-INDUCED EMT

Figure A-1. Pro-Inflammatory Cytokines Are Not Responsible for HAstV-Induced
EMT.
(A) Supernatants collected from HAstV-1 infected Caco-2 cells at 18, 24, and 48 hpi
were UV-inactivated and place onto naïve Caco-2 cells. TER was measured every 15 min
for 21 hours following inoculation with UV supernatants. (B) TNF- levels were
measured in supernatants from HAstV-1 and mock infected cells (24hpi0, as well as
stock virus and purified virus. (C) Caco-2 cells were infected with purified HAstV-1
(MOI 10) and stained for HAstV capsid (green), E-cadherin (red), and DAPI (blue) at 24
hpi.
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APPENDIX B. HASTV DIRECTLY ACTIVATES LATENT TGF-Β

Figure B-1. HAstV Directly Activates Latent TGF-β.
(A) Conditioned media containing latent TGF- from Caco-2 cells was treated with heat
(100C for 10 min), 1N HCl, thrombospondin-1 (TSP-1; 4g/ml), or purified HAstV-1
(10% by volume). Active TGF- was included as a positive control. Samples were then
assayed for active TGF-β using the PAI assay as described previously.344 Error bars
indicate standard deviations.
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APPENDIX C. CLINICAL ISOLATE WITHOUT SEQUENCE HOMOLOGY
TO MIR-487A SHOWS REDUCED EMT CHARACTERISTICS

Figure C-1. Clinical Isolate Without Sequence Homology to miR-487a Shows
Reduced EMT Characteristics.
(A) Sequence homology of lab adapted HAstV-1, and clinical isolates 225, 212, and 110
to miR-487a. Highlighted in red are unacceptable substitutions and yellow are acceptable
substitutions. (B) TER measurements from 0 to 24 hpi with lab adapted HAstV-1 and
clinical isolates 225, 212, and 110. (C) Expression of epithelial marker, E-cadherin, was
quantified by immunoblot of HAstV-1, clinical isolates 225, 212, and 110, or mock
infected Caco-2 cell lysates. Bands were then quantified by densitometry and normalized
to total protein then compared to mock-infection. Error bars indicate standard deviations,
and asterisks show statistical significance as measured by two-way ANOVA followed by
Tukey’s multiple comparisons test as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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APPENDIX D. THE ROLE OF OCCLUDIN IN HASTV INFECTION

Figure D-1. Occludin Knockdown Caco-2 Cells.
Caco-2 cells stably transfected with shRNA directed to occludin show decreased
expression of occludin as compared to scramble shRNA (shCtrl) and wildtype Caco-2
cells. (A) Expression of occludin was quantified by immunoblot of shOCLN, shCtrl, and
Caco-2 cell lysates. (B) Bands were then quantified by densitometry and normalized to actin. Error bars indicate standard deviations.
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Figure D-2. Occludin Knockdown Cells Exhibit Increased Infection.
(A) Caco-2, shOCLN, and shCtrl cells were infected with HAstV-1 (MOI 5). At 24hpi,
the cells were fixed in 100% ice-cold methanol and stained for HAstV capsid (green) and
DAPI (blue). (B) The percentage of infected cells was quantified for each cell type. (C)
Supernatants collected at 24 hpi from HAstV-1-infected Caco-2, shOCLN, and shCtrl
cells were titered, showing no significant difference between the cell types.
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APPENDIX E. HASTV-VA1 ANTIBODIES ARE MORE ABUNDANT THAN
HASTV-1

Figure E-1. HAstV-VA1 Antibodies Are More Abundant than HAstV-1.
Nine lots of commercially available IVIG were tested by ELISA for specificity to
HAstV-1 (A) and HAstV-VA1 (B). Viral titers were analyzed via RT-PCR following
neutralization assay in the supernatant (C) and cell lysate (D) of HAstV-VA1 infected
cells.
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